SEARCH

Search Details

Narita Hisashi

Hokkaido University Hospital Division of Neural and Sensory OrgansLecturer

Researcher basic information

■ Degree
  • 医学博士, 北海道大学
■ URL
researchmap URLホームページURL■ Various IDs
Researcher number
  • 50779874
J-Global ID■ Research Keywords and Fields
Research Keyword
  • リエゾン精神医学
  • 気分障害
  • 統合失調症
  • MRI
  • neuroimaging
Research Field
  • Life Science, Psychiatry
■ Educational Organization

Career

■ Career
Career
  • Jun. 2024 - Present
    北海道大学病院 精神科神経科 講師
  • Apr. 2023 - May 2024
    北海道大学病院 精神科神経科 診療講師(助教)
  • Apr. 2018 - Mar. 2023
    北海道大学病院 精神科神経科, 助教
  • Apr. 2017 - Mar. 2018
    市立稚内病院, 精神科, 主任医長
  • Apr. 2016 - Mar. 2017
    Hokkaido University, Hokkaido University Hospital, 助教
  • Apr. 2012 - Mar. 2016
    北海道大学病院, 精神科神経科, 医員
  • Apr. 2010 - Mar. 2012
    北海道医療センター, 精神科, 医員
  • Apr. 2009 - Mar. 2010
    市立室蘭総合病院, 精神科, 医員
  • Apr. 2008 - Mar. 2009
    Hokkaido University, Hokkaido University Hospital, 後期研修医
  • Apr. 2006 - Mar. 2008
    Hokkaido University, Hokkaido University Hospital, 初期研修医
Educational Background
  • Jul. 2025 - Mar. 2026, Hokkaido several Universities Hospital Management Administration: HUHMA
  • Apr. 2012 - Mar. 2016, 北海道大学大学院大学, 神経病態学講座精神医学分野, 博士課程
  • Apr. 1999 - Mar. 2006, Hokkaido University, School of Medicine, 医学科
Committee Memberships
  • Jun. 2026 - Present
    日本循環器学会, 心不全療養指導士認定部会
  • Feb. 2026 - Present
    日本サイコカーディオロジー学会, 総務委員会
  • Feb. 2026 - Present
    日本サイコカーディオロジー学会, 教育研修委員会, Society
  • Sep. 2025 - Present
    日本総合病院精神医学会, 治療戦略委員会 委員, Society
  • Apr. 2025 - Present
    北海道精神科神経学会, 幹事
  • Jan. 2025 - Present
    日本総合病院精神医学会, 臓器不全・移植関連委員会 副委員長
  • Apr. 2023 - Present
    DPAT 事務局, ワーキンググループ委員
  • Apr. 2022 - Present
    北海道精神医療審査会 委員, Autonomy
  • Jul. 2021 - Present
    北海道社会保険診療報酬審査委員会, 委員
  • 2021 - Present
    日本総合病院精神医学会, 地方会委員会 委員
  • Nov. 2020 - Present
    日本総合病院精神医学会, 評議員, Society
  • Jun. 2018 - Present
    日本精神科救急学会, 代議員, Society
  • 2018 - Present
    躁うつ病懇話会, 幹事
  • 2017 - Present
    緩和ケア研修会モジュール検討会ワーキンググループ, (心不全領域)外部委員, Society
  • 2017 - Present
    日本総合病院精神医学会, 電気けいれん療法委員会 委員, Society
  • Sep. 2023 - Sep. 2025
    日本精神神経学会, 災害支援委員会委員, Society
  • Sep. 2023 - Sep. 2025
    日本精神神経学会, 精神科医療機器委員会委員, Society
  • 2014 - Jan. 2025
    日本総合病院精神医学会, 臓器不全・移植関連委員会 委員, Society

Research activity information

■ Awards
  • Sep. 2025, JSMD-ISBDフェローシップ
  • Jun. 2019, 日本精神神経学会学術総会 第115回学術総会部門, 優秀発表賞
    成田尚
■ Papers
  • 循環器疾患治療薬が精神障害に与える影響と注意点 (精神科医の視点
    Nov. 2026, [Lead author]
  • Association of Affective Temperaments With One‐Year Depressive Outcomes in Middle‐Aged and Older Patients With Mood Disorders Without Psychiatric Comorbidities
    Takashi Ozaki; Hisashi Narita; Shizuka Mito; Niki Udo; Nobuyuki Mitsui; Naoki Hashimoto; Ichiro Kusumi; Takahiro A. Kato
    Neuropsychopharmacology Reports, Sep. 2026, [Corresponding author]
    English, Scientific journal, ABSTRACT

    Aim
    The course of depressive symptoms in mood disorders may be influenced by multiple clinical factors, making predictors of subsequent symptoms difficult to identify. This study examined whether affective temperaments are associated with depressive symptoms at one‐year follow‐up in middle‐aged and older patients with mood disorders without clinically relevant psychiatric comorbidities.


    Methods
    This one‐year longitudinal observational study included 91 patients aged 40–75 years with major depressive disorder (MDD) or bipolar disorder (BD) who were admitted to Hokkaido University Hospital for a recent major depressive episode, completed baseline assessments at discharge, and were followed for 1 year after discharge. Patients with clinically relevant psychiatric comorbidities were excluded. Affective temperaments were assessed using the Temperament Evaluation of Memphis, Pisa, Paris, and San Diego Autoquestionnaire. Multiple linear regression analyses were performed to examine factors associated with the 17‐item Hamilton Depression Rating Scale (HAM‐D17) total score at one‐year follow‐up, and logistic regression analyses to examine factors associated with subthreshold or more severe depressive symptoms at one‐year follow‐up. Temperament‐by‐diagnosis interaction analyses were performed to examine whether these associations differed between MDD and BD. This study was approved by the ethics committee of Hokkaido University Hospital.


    Results
    Depressive and cyclothymic temperaments were significantly associated with a higher HAM‐D17 total score at one‐year follow‐up after adjustment. Depressive temperament was also associated with non‐remission. A significant cyclothymic temperament‐by‐diagnosis interaction was observed.


    Conclusion
    Depressive and cyclothymic temperaments may be clinically relevant for understanding residual depressive symptoms at one‐year follow‐up in middle‐aged and older patients with mood disorders without clinically relevant psychiatric comorbidities. The significant cyclothymic temperament‐by‐diagnosis interaction highlights the potential diagnosis‐specific relevance of affective temperament. Larger prospective studies are required to confirm these findings.
  • うつ病の診断精度と治療選択を高める客観的バイオマーカー:神経画像・末梢血オミクス統合の展望
    成田 尚; 瀬戸山 大; 加藤 隆弘
    臨床精神薬理, Sep. 2026, [Invited], [Lead author]
  • 病院経営における『睡眠障害』を再定義する──患者アウトカム、医療安全を向上し、働き方改革を進めるために
    成田 尚; 石川 修平; 加藤 隆弘
    病院経営羅針盤, Sep. 2026, [Lead author]
  • The matter of Hokkaido
    成田尚
    Jpn J Gen Hosp Psychiatry, 37, 4, Dec. 2025, [Peer-reviewed], [Invited], [Lead author, Last author, Corresponding author]
    Scientific journal
  • Association between higher cerebrospinal fluid levels of phosphorylated tau and reduced depressive symptoms in patients with cognitive decline
    Takashi Ozaki; Naoki Hashimoto; Hisashi Narita; Niki Udo; Shizuka Mito; Shin Nakagawa; Ichiro Kusumi; Takahiro A. Kato
    Psychiatry and Clinical Neurosciences Reports, 4, 4, Wiley, 16 Oct. 2025, [Peer-reviewed]
    English, Scientific journal, Abstract

    Aim

    In individuals with cognitive decline, depressive symptoms can affect disease progression and quality of life. One factor that may be associated with depressive symptoms is phosphorylated tau (p‐tau). However, the association between p‐tau and depressive symptoms remains controversial. The present study examined the relationship between p‐tau levels and depressive symptoms not only in terms of total scale scores of the 15‐item Geriatric Depression Scale (GDS‐15) but also at the item level.

    Methods

    We conducted a cross‐sectional survey of patients (n = 88) with mild cognitive impairment due to Alzheimer's disease (AD) or with AD dementia (ADD), who were strictly diagnosed by a board of psychiatrists and neurologists from Hokkaido University Hospital. All patients underwent lumbar puncture to obtain cerebrospinal fluid for the p‐tau assessment. We first investigated the association between p‐tau level and GDS‐15 total score. Next, we compared the p‐tau levels for each item using the GDS‐15 with binary responses “none (0)” or “present (1).”

    Results

    Multivariable regression analysis revealed that higher levels of p‐tau were significantly associated with lower GDS‐15 total scores (standardized coefficient [95% confidence interval] = −0.28, [−0.48, −0.09]). Furthermore, patients with higher p‐tau levels were less likely to have symptoms of GDS‐15 Items 2 (Dropped interests) (p < 0.001) and 14 (Hopeless) (p = 0.0030).

    Conclusion

    Our findings suggest an association between p‐tau accumulation and reduced depressive symptoms. However, future longitudinal studies are required to confirm whether p‐tau may be a predictive factor for depressive symptoms.
  • Lithium and valproate affect subcortical brain volumes in individuals with bipolar disorder: Mega-analysis of 235 individuals
    Naoki Hashimoto; Naohiro Okada; Masaki Fukunaga; Kiyotaka Nemoto; Kenichiro Miura; Junya Matsumoto; Shuhei Ishikawa; Hisashi Narita; Kentaro Morita; Yuka Yasuda; Toshiharu Kamishikiryo; Kenichiro Harada; Maeri Yamamoto; Kazutaka Ohi; Toshio Matsubara; Yoji Hirano; Go Okada; Khin K. Tha; Osamu Abe; Toshiaki Onitsuka; Yasuhiro Kawasaki; Norio Ozaki; Kiyoto Kasai; Ryota Hashimoto
    Journal of Affective Disorders, Elsevier BV, Apr. 2025, [Peer-reviewed]
    English, Scientific journal
  • Proposal for a Novel Classification of Patients With Enlarged Ventricles and Cognitive Impairment Based on Data‐Driven Analysis of Neuroimaging Results in Patients With Psychiatric Disorders
    Yuka Yasuda; Satsuki Ito; Junya Matsumoto; Naohiro Okada; Toshiaki Onitsuka; Masashi Ikeda; Itaru Kushima; Chika Sumiyoshi; Masaki Fukunaga; Kiyotaka Nemoto; Kenichiro Miura; Naoki Hashimoto; Kazutaka Ohi; Tsutomu Takahashi; Daiki Sasabayashi; Michihiko Koeda; Hidenaga Yamamori; Michiko Fujimoto; Harumasa Takano; Naomi Hasegawa; Hisashi Narita; Maeri Yamamoto; Khin Khin Tha; Masataka Kikuchi; Toshiharu Kamishikiryo; Eri Itai; Yoshiro Okubo; Amane Tateno; Motoaki Nakamura; Manabu Kubota; Hiroyuki Igarashi; Yoji Hirano; Go Okada; Jun Miyata; Shusuke Numata; Osamu Abe; Reiji Yoshimura; Shin Nakagawa; Hidenori Yamasue; Norio Ozaki; Kiyoto Kasai; Ryota Hashimoto
    Neuropsychopharmacology Reports, 45, 1, Wiley, 26 Feb. 2025, [Peer-reviewed]
    English, Scientific journal, ABSTRACT

    One of the challenges in diagnosing psychiatric disorders is that the results of biological and neuroscience research are not reflected in the diagnostic criteria. Thus, data‐driven analyses incorporating biological and cross‐disease perspectives, regardless of the diagnostic category, have recently been proposed. A data‐driven clustering study based on subcortical volumes in 5604 subjects classified into four brain biotypes associated with cognitive/social functioning. Among the four brain biotypes identified in controls and patients with schizophrenia, bipolar disorder, major depressive disorder, autism spectrum disorder, and other psychiatric disorders, we further analyzed the brain biotype 1 subjects, those with an extremely small limbic region, for clinical utility. We found that the representative feature of brain biotype 1 is enlarged lateral ventricles. An enlarged ventricle, defined by an average z‐score of left and right lateral ventricle volumes > 3, had a sensitivity of 99.1% and a specificity of 98.1% for discriminating brain biotype 1. However, the presence of an enlarged ventricle was not sufficient to classify patient subgroups, as 1% of the controls also had enlarged ventricles. Reclassification of patients with enlarged ventricles according to cognitive impairment resulted in a stratified subgroup that included patients with a high proportion of schizophrenia diagnoses, electroencephalography abnormalities, and rare pathological genetic copy number variations. Data‐driven clustering analysis of neuroimaging data revealed subgroups with enlarged ventricles and cognitive impairment. This subgroup could be a new diagnostic candidate for psychiatric disorders. This concept and strategy may be useful for identifying biologically defined psychiatric disorders in the future.
  • Suspected Postpartum Depression Revealed to be CSF1R-Related Leukoencephalopathy: A Case Report
    Masahiko Mikuni; Kazuhiro Horiuchi; Ayako Ishikura; Soichiro Kimura; Sho Masutani; Shinya Watanabe; Akihiro Mikami; Shuhei Ishikawa; Hisashi Narita; Ichiro Kusumi; Hidenao Sasaki
    Case Reports in Neurology, 1, 11, S. Karger AG, 02 Oct. 2024
    English, Scientific journal, Introduction This is a case of a 32-year-old woman who developed postpartum depression (PPD). She became anxious and depressive about caring for her child, and the Edinburgh Postnatal Depression Scale (EPDS) test showed a score of 9 at two weeks after delivery, and at 7 months postpartum, she presented with major melancholic depression followed by mild cognitive decline without any neurological symptoms except cluttering speech. Case Presentation Cerebral MRI showed confluent FLAIR hyperintensities in the periventricular and frontal deep white matter, with multiple spotty calcifications in the frontal white matter by cerebral CT. Genetic testing revealed a mutation in the colony stimulating factor 1 receptor (CSF1R). ConclusionThis case report is consistent with evidence that PPD may have organic causes in some cases, including CSF1R mutations. Atypical findings such as mild cognitive decline combined with PPD in psychiatric interview may justify brain imaging to avoid misdiagnosis, since CSF1R-related leukoencephalopathy is probably an under-recognized disease in medical psychiatry. Further investigations are needed to clarify a pathophysiological correlation between CSF1R signaling abnormality and PPD as well as major depression.
  • 循環器用薬
    成田尚
    症状性・器質性精神障害診療ガイド ―精神症状を引き起こす身体疾患,物質・医薬品―(2024年版), Oct. 2024, [Invited], [Lead author, Corresponding author]
    Scientific journal
  • Validity and reliability of the palliative care needs assessment tool in Japanese patients with heart failure
    Daishiro Tatsuta; Takuma Sato; Toshiyuki Nagai; Jiro Koya; Kotaro Nishino; Seiichiro Naito; Yoshifumi Mizuguchi; Taro Temma; Kiwamu Kamiya; Hisashi Narita; Kenkichi Tsuruga; Toshihisa Anzai
    ESC Heart Failure, Wiley, 29 May 2024
    English, Scientific journal, Abstract

    Aims

    Although patients with heart failure (HF) frequently experience considerable symptom burden and require significant care, most HF patients do not receive timely intervention due to the absence of a standardized method for identifying those in need of palliative care. The Needs Assessment Tool: Progressive Disease‐Heart Failure (NAT: PD‐HF) assesses the palliative care needs of patients with HF. However, its validity and reliability have yet to be fully examined. We aimed to assess the validity and reliability of the NAT: PD‐HF in Japanese patients with HF.

    Methods

    We prospectively enrolled 106 consecutive patients with chronic HF admitted to our university hospital between February 2023 and July 2023. Their caregivers (n = 95) and healthcare providers (n = 17) were also included. The NAT: PD‐HF was translated from English to Japanese using a forward–backward translation procedure and adapted based on Japanese cultural and medical backgrounds by our professional multidisciplinary team. We assessed the internal consistency of the Japanese NAT: PD‐HF version with Cronbach's alpha coefficient and the inter‐rater and test–retest reliabilities with Cohen's kappa coefficient. After using the tool, all participants were asked to complete a questionnaire about the tool to determine its validity.

    Results

    The proportion of female patients in this study was 47 (44%). The median age was 72 years [interquartile range (IQR) 59–81]. The median time spent assessing the patients' and their caregivers' needs using the Japanese NAT: PD‐HF was 14 min (IQR 12–17). The Cronbach's alpha coefficient was 0.82, and the minimum kappa coefficient was 0.77 for inter‐rater reliability and 0.88 for test–retest reliability. In total, 103 patients (97%) and all caregivers responded that the tool was easy to understand. One hundred (94%) patients and 89 (94%) caregivers felt that the tool would improve the quality of care, and 102 (96%) patients and 91 (96%) caregivers indicated that the discussions using this tool allowed them to confide in all their burdens and care needs. All healthcare providers expressed that this tool is helpful in understanding the burden and care needs of both patients and caregivers comprehensively.

    Conclusions

    The NAT: PD‐HF is a reliable and valid tool for Japanese patients with HF and their caregivers. This tool was very well accepted by patients, caregivers and healthcare providers to identify burdens and care needs.
  • 双極症 入院治療 入院中の躁転・うつ転への対応
    成田尚
    精神科Resident, 5, 2, 2024, [Invited], [Lead author]
  • Abstract 13743: Validity and Reliability of a Palliative Care Needs Assessment Tool in Japanese Patients With Heart Failure
    Daishiro Tatsuta; Takuma Sato; Toshiyuki Nagai; Jiro Koya; Kotaro Nishino; Seiichiro Naito; Yoshifumi Mizuguchi; Taro Temma; Kiwamu Kamiya; Hisashi Narita; Kenkichi Tsuruga; Toshihisa Anzai
    Circulation, 148, Ovid Technologies (Wolters Kluwer Health), 07 Nov. 2023
    Backgrounds: Although patients with heart failure (HF) frequently experience considerable symptom burden and require significant care similar to those with cancer, most HF patients do not receive timely intervention due to the absence of standardized method for identifying those in need of palliative care. Several tools have been employed to assess palliative care needs and identify eligible patients. However, their validity and reliability have yet to be fully examined worldwide. We sought to assess the validity and reliability of The Needs Assessment Tool: Progressive Disease-Heart Failure (NAT: PD-HF) in Japanese HF population. Methods: We enrolled consecutive HF patients admitted in our university hospital between February and May 2023 and their caregivers were also included. The NAT: PD-HF were translated into Japanese by our professional multidisciplinary team in accordance with cultural and medical background. We assessed the internal consistency of the NAT: PD-HF with Cronbach`s alpha, and the inter-rater and test-retest reliability with Cohen`s kappa. After using this tool, patients, caregivers, and health care providers were asked whether the tool adequately identify their burden and care needs. Results: During the study period, 75 patients, 67 caregivers, and 17 health care providers agreed to participate. Cronbach's alpha was 0.80 and the minimum Kappa coefficient was 0.73 for inter-rater reliability and 0.83 for test-retest reliability. Seventy-one patients (94%) and 64 caregivers (95%) found this tool useful to identify their burden and care needs. Seventy patients (93%) and 63 caregivers (94%) felt that the tool will improve the quality of care. Sixteen health care providers (94%) also believed this tool was helpful to understand the burden and care needs of both patients and caregivers. However, 7 of them (41%) considered they may not have enough time to use the tool in their daily clinical practice. Conclusions: The NAT: PD-HF was suggested to be a reliable and potentially valid tool even among Japanese HF patients. This tool was very well accepted by patients, caregivers, and health care providers to identify burden and care needs. Further follow-up studies are needed to examine the prognostic impact of using this tool.
  • Neurobiological correlation between phosphorylated tau and mood symptoms in memory clinic patients
    Takashi Ozaki; Naoki Hashimoto; Niki Udo; Hisashi Narita; Shin Nakagawa; Ichiro Kusumi
    Psychogeriatrics, Wiley, 08 Oct. 2023
    Scientific journal, Background

    Alzheimer's disease (AD) dementia and mild cognitive impairment are characterised by impaired cognition accompanied by neuropsychiatric symptoms (NPS) relating to mood, including depression, anxiety, and apathy. However, the utility of AD biomarkers for predicting mood symptoms of NPS remains controversial. Herein, we analyzed the relationship between phosphorylated tau (p‐tau) and depression, anxiety, and apathy of NPS. We also examined the influence of genetic factors such as apolipoprotein E (APOE) ε4 on these relationships.

    Methods

    We conducted a cross‐sectional survey in older patients (n = 122) with normal cognition (n = 12), mild cognitive impairment (n = 46), and AD (n = 64) strictly diagnosed by the board of psychiatrists and neurologists of Hokkaido University. NPS of the patients were assessed using the Neuropsychiatric Inventory Questionnaire (NPI). All patients also received a lumbar puncture to obtain cerebral spinal fluid for assessment of p‐tau. The inverse probability weighting method was used to adjust for demographic differences between the p‐tau present group and the p‐tau absent group.

    Results

    There was an association between p‐tau accumulation and decreased incidence of depression and apathy. APOE ε4 non‐carriers also showed a trend toward a negative association between p‐tau and depression, which was not evident in APOE ε4 carriers.

    Conclusions

    We provide new evidence for a negative correlation between p‐tau and depression and apathy of NPS, which may be influenced by APOE ε4. Future longitudinal studies are required to confirm the utility of p‐tau for predicting the course of mood symptoms in patients with cognitive decline.
  • Cardiovascular adverse reactions associated with escitalopram in patients with underlying cardiovascular diseases: a systematic review and meta-analysis
    Kenichi Kimura; Hisashi Narita; Hissei Imai; Hisashi Akiyama; Shuhei Ishikawa; Ryo Sawagashira; Tomoyuki Isoyama; Mariko Nohara; Michiyo Kawamura; Yukari Kono; Takuya Saito; Ichiro Kusumi
    Frontiers in Psychiatry, 14, Frontiers Media SA, 22 Sep. 2023, [Peer-reviewed], [Corresponding author]
    Scientific journal, Background

    Despite the anticipated efficacy of escitalopram in treating depression and anxiety in individuals with preexisting cardiovascular conditions, persistent concerns regarding its adverse effects have emerged. In this systematic review, we aimed to evaluate the cardiovascular safety profile of escitalopram compared with that of placebo in patients with underlying cardiovascular disease.

    Methods

    We used a predefined search strategy in PubMed, Cochrane Central Register of Controlled Trials, Embase, International Clinical Trials Registry Platform, and ClinicalTrials.gov to identify studies evaluating adverse cardiovascular reactions to escitalopram in patients with underlying cardiovascular disease. Randomized controlled trials (RCTs) that provided results on cardiovascular safety outcomes were included. Two independent reviewers screened the abstracts and full texts of the individual studies. The risk of bias was assessed using version 2 of the Cochrane risk-of-bias tool for randomized trials. The certainty of evidence was assessed using the Grading of Recommendations, Assessment, Development, and Evaluation approach.

    Results

    The primary outcomes were the frequency of major adverse cardiovascular events (MACE), QTc prolongation, and discontinuation of study medication. We identified 5 RCTs with 773 participants who met the inclusion criteria. Escitalopram was not associated with significantly increased risk of MACE (risk ratio [RR] = 1.85; 95% confidence interval [CI] 0.80 to 4.26; I2 0%; 5 RCTs; n = 773, moderate certainty of evidence), discontinuation of study medication (RR = 1.03; 95% CI 0.84–1.26; I2 0%; 5 RCTs; n = 773, low certainty of evidence), and QTc prolongation (RR = 1.20; 95% CI 0.76–1.90; I2 0%; 4 RCTs; n = 646, low certainty of evidence).

    Conclusion

    Escitalopram does not significantly increase the risk of cardiovascular adverse reactions compared with placebo in patients with underlying cardiovascular disease. However, the presence of wide CIs and the limited number of included studies highlight the need for further studies with larger sample sizes to enhance the precision and reliability of these findings.

    Systematic review registration: International Prospective Register of Systematic Reviews [CRD42022298181].
  • Differences in acute outcomes of suicide patients by psychiatric disorder: Retrospective observational study
    Takumi Tsuchida; Masaki Takahashi; Asumi Mizugaki; Hisashi Narita; Takeshi Wada
    Medicine, 102, 38, e35065, e35065, Ovid Technologies (Wolters Kluwer Health), 22 Sep. 2023, [Peer-reviewed]
    English, Scientific journal, Suicide is a social problem with significant economic losses, the victims of which are mainly from the productive population. There are numerous reports on the assessment of suicide risk, but most focus on long-term management. Therefore, factors influencing the severity of physical impairments in the acute phase and the prognosis of suicidal patients have not been sufficiently investigated. This is a single-center retrospective observational study. We collected data on suicidal patients admitted to our emergency department. The effect of age, gender, psychiatric history, method of suicide, alcohol consumption, and hospital admission on the outcome of suicide was assessed. Outcomes were assessed using the hospital mortality scale and the cerebral performance category scale for in-hospital mortality within 28 days. Methods of suicide with a high mortality rate (hanging, jumping, carbon monoxide poisoning, and burns) were defined as lethal methods. A detailed risk assessment of outcomes was performed for patients with schizophrenia, mood disorders, and somatoform disorders. We identified 340 suicide patients from computerized medical records and analyzed 322 records without missing data. The non-survivor group predominantly comprised older adults, men, and patients without a history of psychiatric treatment. Contrastingly, more patients drank alcohol before suicide in the survivor group. In the subgroup analysis, patients with schizophrenia had unfavorable neurological outcomes. Patients with mood disorders had worse in-hospital mortality than other psychiatric patients, as did patients who chose the lethal method. By disease, patients with stress-related and somatoform disorders tended to have higher survival rates, although their psychiatric hospitalization rates were lower. Conversely, patients with mood disorders had a higher rate of hospital visits but a lower survival rate. The results suggest that usual outpatient treatment alone may not be sufficient to reduce suicide mortality in patients with mood disorders who are considered to be at high risk of suicide.
  • クロザピン誘発発作に対する抗痙攣薬の使用 統合失調症患者における後ろ向き研究(Use of Anti-Seizure Medications for Clozapine-Induced Seizures: A Retrospective Study in Patients with Schizophrenia)
    堀之内 徹; 中村 悠一; 石川 修平; 橋本 直樹; 成田 尚; 三井 信幸; 賀古 勇輝; 久住 一郎
    てんかん研究, 41, 2, 319, 319, (一社)日本てんかん学会, Sep. 2023
    English
  • 生体移植ドナーの精神的・身体的サポート 生体肝移植ドナーの併存精神疾患と精神科連携
    木村 宏之; 杉田 尚子; 大橋 綾子; 成田 尚; 藤澤 大介; 岡田 剛史; 松本 洋輔; 岸 辰一; 川崎 弘詔; 西村 勝治; 小倉 靖弘; 池田 匡志; 日本総合病院精神医学会臓器不全・移植関連委員会
    移植, 58, 総会臨時, 116, 116, (一社)日本移植学会, Sep. 2023
    Japanese
  • Cerebral cortical structural alteration patterns across four major psychiatric disorders in 5549 individuals
    Junya Matsumoto; Masaki Fukunaga; Kenichiro Miura; Kiyotaka Nemoto; Naohiro Okada; Naoki Hashimoto; Kentaro Morita; Daisuke Koshiyama; Kazutaka Ohi; Tsutomu Takahashi; Michihiko Koeda; Hidenaga Yamamori; Michiko Fujimoto; Yuka Yasuda; Satsuki Ito; Ryuichi Yamazaki; Naomi Hasegawa; Hisashi Narita; Satoshi Yokoyama; Ryo Mishima; Jun Miyata; Yuko Kobayashi; Daiki Sasabayashi; Kenichiro Harada; Maeri Yamamoto; Yoji Hirano; Takashi Itahashi; Masahito Nakataki; Ryu-ichiro Hashimoto; Khin K. Tha; Shinsuke Koike; Toshio Matsubara; Go Okada; Reiji Yoshimura; Osamu Abe; Theo G. M. van Erp; Jessica A. Turner; Neda Jahanshad; Paul M. Thompson; Toshiaki Onitsuka; Yoshiyuki Watanabe; Koji Matsuo; Hidenori Yamasue; Yasumasa Okamoto; Michio Suzuki; Norio Ozaki; Kiyoto Kasai; Ryota Hashimoto
    Molecular Psychiatry, Springer Science and Business Media LLC, 18 Aug. 2023
    English, Scientific journal, Abstract

    According to the operational diagnostic criteria, psychiatric disorders such as schizophrenia (SZ), bipolar disorder (BD), major depressive disorder (MDD), and autism spectrum disorder (ASD) are classified based on symptoms. While its cluster of symptoms defines each of these psychiatric disorders, there is also an overlap in symptoms between the disorders. We hypothesized that there are also similarities and differences in cortical structural neuroimaging features among these psychiatric disorders. T1-weighted magnetic resonance imaging scans were performed for 5,549 subjects recruited from 14 sites. Effect sizes were determined using a linear regression model within each protocol, and these effect sizes were meta-analyzed. The similarity of the differences in cortical thickness and surface area of each disorder group was calculated using cosine similarity, which was calculated from the effect sizes of each cortical regions. The thinnest cortex was found in SZ, followed by BD and MDD. The cosine similarity values between disorders were 0.943 for SZ and BD, 0.959 for SZ and MDD, and 0.943 for BD and MDD, which indicated that a common pattern of cortical thickness alterations was found among SZ, BD, and MDD. Additionally, a generally smaller cortical surface area was found in SZ and MDD than in BD, and the effect was larger in SZ. The cosine similarity values between disorders were 0.945 for SZ and MDD, 0.867 for SZ and ASD, and 0.811 for MDD and ASD, which indicated a common pattern of cortical surface area alterations among SZ, MDD, and ASD. Patterns of alterations in cortical thickness and surface area were revealed in the four major psychiatric disorders. To our knowledge, this is the first report of a cross-disorder analysis conducted on four major psychiatric disorders. Cross-disorder brain imaging research can help to advance our understanding of the pathogenesis of psychiatric disorders and common symptoms.
  • Subcortical volumetric alterations in four major psychiatric disorders: a mega-analysis study of 5604 subjects and a volumetric data-driven approach for classification
    Naohiro Okada; Masaki Fukunaga; Kenichiro Miura; Kiyotaka Nemoto; Junya Matsumoto; Naoki Hashimoto; Masahiro Kiyota; Kentaro Morita; Daisuke Koshiyama; Kazutaka Ohi; Tsutomu Takahashi; Michihiko Koeda; Hidenaga Yamamori; Michiko Fujimoto; Yuka Yasuda; Naomi Hasegawa; Hisashi Narita; Satoshi Yokoyama; Ryo Mishima; Takahiko Kawashima; Yuko Kobayashi; Daiki Sasabayashi; Kenichiro Harada; Maeri Yamamoto; Yoji Hirano; Takashi Itahashi; Masahito Nakataki; Ryu-ichiro Hashimoto; Khin K. Tha; Shinsuke Koike; Toshio Matsubara; Go Okada; Theo G. M. van Erp; Neda Jahanshad; Reiji Yoshimura; Osamu Abe; Toshiaki Onitsuka; Yoshiyuki Watanabe; Koji Matsuo; Hidenori Yamasue; Yasumasa Okamoto; Michio Suzuki; Jessica A. Turner; Paul M. Thompson; Norio Ozaki; Kiyoto Kasai; Ryota Hashimoto
    Molecular Psychiatry, Springer Science and Business Media LLC, 04 Aug. 2023, [Peer-reviewed]
    English, Scientific journal, Abstract

    Differential diagnosis is sometimes difficult in practical psychiatric settings, in terms of using the current diagnostic system based on presenting symptoms and signs. The creation of a novel diagnostic system using objective biomarkers is expected to take place. Neuroimaging studies and others reported that subcortical brain structures are the hubs for various psycho-behavioral functions, while there are so far no neuroimaging data-driven clinical criteria overcoming limitations of the current diagnostic system, which would reflect cognitive/social functioning. Prior to the main analysis, we conducted a large-scale multisite study of subcortical volumetric and lateralization alterations in schizophrenia, bipolar disorder, major depressive disorder, and autism spectrum disorder using T1-weighted images of 5604 subjects (3078 controls and 2526 patients). We demonstrated larger lateral ventricles volume in schizophrenia, bipolar disorder, and major depressive disorder, smaller hippocampus volume in schizophrenia and bipolar disorder, and schizophrenia-specific smaller amygdala, thalamus, and accumbens volumes and larger caudate, putamen, and pallidum volumes. In addition, we observed a leftward alteration of lateralization for pallidum volume specifically in schizophrenia. Moreover, as our main objective, we clustered the 5,604 subjects based on subcortical volumes, and explored whether data-driven clustering results can explain cognitive/social functioning in the subcohorts. We showed a four-biotype classification, namely extremely (Brain Biotype [BB] 1) and moderately smaller limbic regions (BB2), larger basal ganglia (BB3), and normal volumes (BB4), being associated with cognitive/social functioning. Specifically, BB1 and BB2–3 were associated with severe and mild cognitive/social impairment, respectively, while BB4 was characterized by normal cognitive/social functioning. Our results may lead to the future creation of novel biological data-driven psychiatric diagnostic criteria, which may be expected to be useful for prediction or therapeutic selection.
  • 身体拘束と深部静脈血栓症
    成田尚
    精神科救急, 26, 33, 37, (一社)日本精神科救急学会, Aug. 2023, [Peer-reviewed], [Invited], [Lead author, Corresponding author]
    Japanese
  • 4大精神疾患の大脳構造の類似度の解析 大脳皮質厚と大脳皮質表面積の多施設共同疾患横断解析
    松本 純弥; 福永 雅喜; 三浦 健一郎; 根本 清貴; 岡田 直大; 橋本 直樹; 森田 健太郎; 越山 太輔; 大井 一高; 高橋 努; 肥田 道彦; 山森 英長; 藤本 美智子; 安田 由華; 伊藤 颯姫; 山崎 龍一; 長谷川 尚美; 成田 尚; 横山 仁史; 三嶋 亮; 宮田 淳; 小林 祐子; 笹林 大樹; 原田 健一郎; 山本 真江里; 平野 羊嗣; 板橋 貴史; 中瀧 理仁; 橋本 龍一郎; タ・キンキン; 小池 進介; 松原 敏郎; 岡田 剛; 吉村 玲児; 阿部 修; 鬼塚 俊明; 渡邊 嘉之; 松尾 幸治; 山末 英典; 岡本 泰昌; 鈴木 道雄; 尾崎 紀夫; 笠井 清登; 橋本 亮太
    国立精神・神経医療研究センター精神保健研究所年報, 36, 210, 210, (国研)国立精神・神経医療研究センター精神保健研究所, Jul. 2023
    Japanese
  • クロザピンによる過活動膀胱の発現メカニズムの解明と臨床的指標の探索
    可児 涼真; 成田 尚; 石川 修平; 久住 一郎
    精神神経学雑誌, 2023特別号, S577, S577, (公社)日本精神神経学会, Jun. 2023
    Japanese
  • Comorbid psychiatric disorders and long-term survival after liver transplantation in transplant facilities with a psychiatric consultation-liaison team: a multicenter retrospective study.
    Hiroyuki Kimura; Shinichi Kishi; Hisashi Narita; Teruaki Tanaka; Tsuyoshi Okada; Daisuke Fujisawa; Naoko Sugita; Shun'ichi Noma; Yosuke Matsumoto; Ayako Ohashi; Hiroshi Mitsuyasu; Keizo Yoshida; Hiroaki Kawasaki; Katsuji Nishimura; Yasuhiro Ogura; Norio Ozaki
    BMC gastroenterology, 23, 1, 106, 106, Research Square Platform LLC, 05 Apr. 2023, [Peer-reviewed], [International Magazine]
    English, Scientific journal, Abstract

    Objective Comorbid psychiatric disorders negatively affect the survival rate of patients with some physical disorders. In liver transplant recipients, various psychiatric disorders have been identified as worsening prognosis. However, little is known about how the presence of any comorbid (overall) disorders affect the survival rate of transplant recipients. In this study, we examined the effect of overall comorbid psychiatric disorders on survival rate in liver transplant recipients.Methods A total of 1006 recipients who underwent liver transplantation between September 1997 and July 2017 across eight transplant facilities with a psychiatric consultation-liaison team were identified consecutively. Recipients were categorized into those with comorbid psychiatric disorders and those without comorbid psychiatric disorders. In the comorbid psychiatric disorder group, psychiatric disorder diagnosis and time of diagnosis were investigated retrospectively.Results Of the 1006 recipients, 294 (29.2%) had comorbid psychiatric disorders. Comorbid psychiatric disorders in the 1006 recipients were insomnia (N = 107, 10.6%), delirium (N = 103, 10.2%), major depressive disorder (N = 41, 4.1%), adjustment disorder (N = 19, 1.9%), anxiety disorder (N = 17, 1.7%), intellectual disability (N = 11, 1.1%), autism spectrum disorder (N = 7, 0.7%), somatic symptom disorder (N = 4, 0.4%) schizophrenia (N = 4, 0.4%), substance use disorder (N = 24, 2.4%) and personality disorder (N = 2, 0.2%). The most common time of psychiatric disorder diagnosis was within the first 3 months after liver transplantation (51.6%). The final mortality in patients with comorbid psychiatric disorder diagnosis during the five periods (pretransplant, transplant to 3 months, months to 1 year, 1 to 3 years, and over 3 years posttransplant) was 16.2%, 18.8%, 39.1%, 28.6%, and 16.2% respectively, and there were no significant differences between the five periods (χ2=8.05, df = 4, p = 0.09). Overall comorbid psychiatric disorders were significantly associated with shorter survival time (log-rank test: p = 0.01, hazard ratio: 1.60 [95% confidence interval: 1.15–2.24], survival rate at the endpoint [%]: 62.0 vs. 83.3). However, after adjusting for confounding variables using Cox proportional hazards regression, there was no significant effect of overall comorbid psychiatric disorders on prognosis.Conclusion Comorbid psychiatric disorders did not affect the survival rate of liver transplant recipients in this study.
  • Dynamics of corticocortical brain functional connectivity relevant to therapeutic response to biologics in inflammatory arthritis.
    Kodai Sakiyama; Nobuya Abe; Yuichiro Fujieda; Khin K Tha; Hisashi Narita; Kohei Karino; Masatoshi Kanda; Michihito Kono; Masaru Kato; Tatsuya Atsumi
    Cerebral cortex (New York, N.Y. : 1991), 33, 13, 8342, 8351, Oxford University Press ({OUP}), 01 Apr. 2023, [International Magazine]
    English, Scientific journal, Aberrant functional connectivity (FC) of the brain regions, evaluated by functional magnetic resonance imaging (fMRI), affects clinical courses in inflammatory arthritis (IA). The static analysis methods would be simplistic to estimate the whole picture of resting-state brain function because blood oxygen level-dependent (BOLD) signals fluctuate over time. The effects of FC dynamics on clinical course are unknown in IA. Therefore, we aimed to evaluate dynamic FC for therapeutic responsiveness to biologics in IA patients. We analyzed resting-state fMRI data of 64 IA patients in 2 cohorts. Dynamic FC was derived as a correlation coefficient of the windowed BOLD signal time series. We determined representative whole-brain dynamic FC patterns by k-means++ cluster analysis, leading to 4 distinct clusters. In the first cohort, occurrence probability of the distinct cluster was associated with favorable therapeutic response in disease activity and patients' global assessment, which was validated by the second cohort. The whole-brain FC of the distinct cluster indicated significantly increased corticocortical connectivity, and probabilistically decreased after therapy in treatment-effective patients compared with -ineffective patients. Taken together, frequent emergence of corticocortical connections was associated with clinical outcomes in IA. The coherence of corticocortical interactions might affect pain modulation, possibly relevant to therapeutic satisfaction.
  • Immediate and 6-month seizure outcomes following first and second SARS-CoV2 mRNA vaccinations: A multicenter study with a nationwide survey.
    Megumi Nonaka; Shuichiro Neshige; Hidetada Yamada; Haruka Ishibashi; Yoshiko Takebayashi; Masahiro Nakamori; Shiro Aoki; Yu Yamazaki; Takeo Shishido; Dai Agari; Kazuhide Ochi; Koji Iida; Hirofumi Maruyama
    Epilepsy & behavior : E&B, 139, 109070, 109070, 03 Jan. 2023, [International Magazine]
    English, Scientific journal, OBJECTIVE: This study aimed to identify seizure outcomes in people with epilepsy (PWE) following severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) messenger RNA vaccination. METHODS: We examined PWE (n = 332, age ≥ 14 years) treated in four tertiary hospitals between 2021 and 2022 to assess the incidence of seizure worsening following vaccination using closed questions. We identified the clinical factors associated with worsening and 6-month vaccination outcomes. We also conducted a nationwide survey on self-reported seizure worsening using open questions, to which 261 general practitioners from 99 institutes contributed. RESULTS: Of the 282 PWE vaccinated in the four hospitals, 16 (5.7%) exhibited seizure worsening; most of them emerged within 48 h of vaccination and were not sustained. Thus, all PWE were at baseline condition 6 months after their vaccination. PWE with seizure worsening were more significantly associated with focal impaired awareness seizures (p < 0.001), high seizure frequency (p = 0.025), and drug-resistant epilepsy (p = 0.007) at baseline compared to PWE without worsening. Multivariate logistic regression analysis revealed that focal impaired awareness seizures were independently associated with worsening (odds ratio, 7.0; 95% confidence interval, 1.50-32.77). A nationwide survey of 5156 PWE data (real-world data) confirmed an extremely low incidence rate of self-reported seizure worsening (0.43%). SIGNIFICANCE: Some PWE, particularly refractory focal epilepsy, exhibit seizure worsening. However, the worsening events were infrequent, non-sustainable, and probably under-reported by PWE, suggesting that there is little evidence that worsening seizures discourage current and future vaccinations.
  • 末期心不全患者の難治性不整脈に対するICD治療機能停止(deactivation)の検討を多職種で行った一例
    甲谷 次郎; 佐藤 琢真; 立田 大志郎; 西野 広太郎; 小林 雄太; 成田 尚; 敦賀 健吉; 青陽 千果; 池田 陽子; 小島 尚子; 古山 勇気; 小野田 紘子; 加藤 美香; 永井 利幸; 安斉 俊久
    日本心臓病学会学術集会抄録, 70回, C, 3, (一社)日本心臓病学会, Sep. 2022
    Japanese
  • 多施設共同研究による統合失調症・双極性障害・うつ病・自閉スペクトラム症の疾患横断的大脳皮質構造画像解析
    松本 純弥; 福永 雅喜; 三浦 健一郎; 根本 清貴; 岡田 直大; 橋本 直樹; 森田 健太郎; 越山 太輔; 大井 一高; 高橋 努; 肥田 道彦; 山森 英長; 藤本 美智子; 安田 由華; 長谷川 尚美; 成田 尚; 横山 仁史; 三嶋 亮; 河島 孝彦; 小林 祐子; 笹林 大樹; 原田 健一郎; 山本 真江里; 平野 羊嗣; 板橋 貴史; 中瀧 理仁; 橋本 龍一郎; タ・キンキン; 小池 進介; 松原 敏郎; 岡田 剛; 吉村 玲児; 阿部 修; 鬼塚 俊明; 渡邊 嘉之; 松尾 幸治; 山末 英典; 岡本 泰昌; 鈴木 道雄; 尾崎 紀夫; 笠井 清登; 橋本 亮太
    国立精神・神経医療研究センター精神保健研究所年報, 35, 202, 202, (国研)国立精神・神経医療研究センター精神保健研究所, Jun. 2022
    Japanese
  • Unguided Computer-Assisted Self-Help Interventions Without Human Contact in Patients With Obsessive-Compulsive Disorder: Systematic Review and Meta-analysis
    Hissei Imai; Aran Tajika; Hisashi Narita; Naoki Yoshinaga; Kenichi Kimura; Hideki Nakamura; Nozomi Takeshima; Yu Hayasaka; Yusuke Ogawa; Toshi Furukawa
    Journal of Medical Internet Research, 24, 4, e35940, e35940, JMIR Publications Inc., 21 Apr. 2022, [Peer-reviewed], [International Magazine]
    English, Scientific journal, Background

    Computer-assisted treatment may reduce therapist contact and costs and promote client participation. This meta-analysis examined the efficacy and acceptability of an unguided computer-assisted therapy in patients with obsessive-compulsive disorder (OCD) compared with a waiting list or attention placebo.

    Objective

    This study aimed to evaluate the effectiveness and adherence of computer-assisted self-help treatment without human contact in patients with OCD using a systematic review and meta-analysis approach.

    Methods

    Randomized controlled trials with participants primarily diagnosed with OCD by health professionals with clinically significant OCD symptoms as measured with validated scales were included. The interventions included self-help treatment through the internet, computers, and smartphones. We excluded interventions that used human contact. We conducted a search on PubMed, Cochrane Central Register of Controlled Trials, EMBASE, World Health Organization International Clinical Trials Registry Platform, and ClinicalTrials.gov, as well as the reference lists of the included studies. The risk of bias was evaluated using version 2 of the Cochrane risk-of-bias tool for randomized trials. We calculated the standardized mean differences for continuous outcomes and risk ratios for dichotomous outcomes. The primary outcomes were short-term improvement of OCD symptoms measured by validated scales and dropout for any reason.

    Results

    We included 11 randomized controlled trials with a total of 983 participants. The results indicated that unguided computer-assisted self-help therapy was significantly more effective than a waiting list or psychological placebo (standard mean difference −0.47, 95% CI −0.73 to −0.22). Unguided computer-assisted self-help therapy had more dropouts for any reason than waiting list or psychological placebo (risk ratio 1.98, 95% CI 1.21 to 3.23). However, the quality of evidence was very low because of the risk of bias and inconsistent results among the included studies. The subgroup analysis showed that exposure response and prevention and an intervention duration of more than 4 weeks strengthen the efficacy without worsening acceptability. Only a few studies have examined the interaction between participants and systems, and no study has used gamification. Most researchers only used text-based interventions, and no study has used a mobile device. The overall risk of bias of the included studies was high and the heterogeneity of results was moderate to considerable.

    Conclusions

    Unguided computer-assisted self-help therapy for OCD is effective compared with waiting lists or psychological placebo. An exposure response and prevention component and intervention duration of more than 4 weeks may strengthen the efficacy without worsening the acceptability of the therapy.

    Trial Registration

    PROSPERO (International Prospective Register of Systematic Reviews) CRD42021264644; https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=264644
  • Aberrant functional connectivity between anterior cingulate cortex and left insula in association with therapeutic response to biologics in inflammatory arthritis
    Nobuya Abe; Yuichiro Fujieda; Khin K. Tha; Hisashi Narita; Kuniyuki Aso; Kohei Karino; Masatoshi Kanda; Michihito Kono; Masaru Kato; Olga Amengual; Tatsuya Atsumi
    Seminars in Arthritis and Rheumatism, 55, 151994, 151994, Elsevier BV, Mar. 2022, [Peer-reviewed], [International Magazine]
    English, Scientific journal, BACKGROUND: Brain activity is reported to be associated with individual pain susceptibility and inflammatory status, possibly contributing to disease activity assessment in inflammatory arthritis (IA) including rheumatoid arthritis (RA) and spondyloarthritis (SpA). However, what alteration of brain function associated with disease activity and therapeutic effectiveness in IA remains unclear. We aimed to identify the alterations of brain functional connectivity (FC) shared in both RA and SpA, and evaluate its relationship to anti-rheumatic treatment response using functional magnetic resonance imaging (MRI). PATIENTS AND METHODS: Structural and resting-state functional MRI data were acquired from patients with IA, patients with osteoarthritis (OA) and heathy controls (HCs). Two datasets were adopted to derive (51 IA, 56 OA, and 17 HCs) and validate (31 IA) the observations. 33 IA patients in the derivation dataset and all the patients in validation dataset required biological treatment and were clinically evaluated before and after therapy. Via whole-brain pair-wise FC analyses, we analyzed IA-specific FC measures relevant to therapeutic response to biologics. RESULTS: The value of FC between left insular cortex (IC) and anterior cingulate cortex (ACC) was significantly low in IA patients compared with OA patients and HCs. We demonstrated that the FC between left anterior long insular gyrus as a subdivision of IC and ACC was significantly associated with therapeutic response to biologics regarding the improvement of patients' global assessment (PGA) in both derivation and validation datasets. CONCLUSION: Disease-specific resting-state FC provides a means to assess the therapeutic improvement of PGA and would be a clinical decision-making tool with predictability for treatment response in both RA and SpA.
  • 今日の精神科治療ハンドブック2021年版 第15章コンサルテーション・リエゾン 2.心疾患にともなう精神障害
    成田 尚
    精神科治療学Vol36 増刊号, Oct. 2021, [Invited], [Lead author]
    Scientific journal
  • 臓器移植希望者(レシピエント)の心理社会的評価に関する提言
    西村 勝治; 井上 真一郎; 大橋 綾子; 岡田 剛史; 桂川 修一; 木村 宏之; 小林 清香; 成田 尚; 中西 健二; 松本 洋輔; 日本総合病院精神医学会臓器不全・臓器移植関連委員会
    総合病院精神医学, 33, 3, 246, 285, (一社)日本総合病院精神医学会, Jul. 2021
    Japanese
  • 臓器移植希望者(レシピエント)の心理社会的評価に関する提言
    西村 勝治; 井上 真一郎; 大橋 綾子; 岡田 剛史; 桂川 修一; 木村 宏之; 小林 清香; 成田 尚; 中西 健二; 松本 洋輔; 日本総合病院精神医学会臓器不全・臓器移植関連委員会
    総合病院精神医学, 33, 3, 246, 285, (一社)日本総合病院精神医学会, Jul. 2021
    Japanese
  • 臓器移植希望者(レシピエント)の心理社会的評価に関する提言
    西村勝治、井上真一郎、大橋綾子、岡田剛史、桂川修一、木村宏之、小林清香、成田尚、中西健二、松本洋介
    総合病院精神医学, 33, 3, 245, 372, Jul. 2021, [Invited]
  • 【これでわかるECTと薬物療法のcutting edge】気分障害におけるECTと薬物療法の位置付けについて
    成田 尚
    臨床精神薬理, 23, 12, 1215, 1222, (株)星和書店, Dec. 2020, [Invited], [Lead author, Corresponding author]
    Japanese
  • A pilot validation study of the Japanese translation of the Positive and Negative Syndrome Scale (PANSS).
    Naoki Hashimoto; Katsuyoshi Takahashi; Daisuke Fujisawa; Kumi Aoyama; Atsuo Nakagawa; Naoe Okamura; Atsuhito Toyomaki; Matsuhiko Oka; Keisuke Takanobu; Ryo Okubo; Hisashi Narita; Kan Kitagawa; Niki Udo; Tamaki Maeda; Shinya Watanabe; Yuka Oyanagi; Akane Miyazaki; Koki Ito; Ichiro Kusumi
    Asian journal of psychiatry, 54, 102210, 102210, 16 Jun. 2020, [Peer-reviewed], [International Magazine]
    English, Scientific journal
  • Microstructural Alterations in Bipolar and Major Depressive Disorders: A Diffusion Kurtosis Imaging Study.
    Daisuke Sawamura; Hisashi Narita; Naoki Hashimoto; Shin Nakagawa; Hiroyuki Hamaguchi; Noriyuki Fujima; Kohsuke Kudo; Hiroki Shirato; Khin K Tha
    Journal of magnetic resonance imaging : JMRI, 52, 4, 1187, 1196, 23 Apr. 2020, [Peer-reviewed], [International Magazine]
    English, Scientific journal, BACKGROUND: Identifying structural and functional abnormalities in bipolar (BD) and major depressive disorders (MDD) is important for understanding biological processes. HYPOTHESIS: Diffusion kurtosis imaging (DKI) may be able to detect the brain's microstructural alterations in BD and MDD and any differences between the two. STUDY TYPE: Prospective. SUBJECTS: In all, 16 BD patients, 19 MDD patients, and 20 age- and gender-matched healthy volunteers. FIELD STRENGTH/SEQUENCE: DKI at 3.0T. ASSESSMENT: The major DKI indices of the brain were compared voxel-by-voxel among the three groups. Significantly different voxels were tested for correlation with clinical variables (ie, Young Mania Rating Scale [YMRS], 17-item Hamilton Depression Rating Scale [17-HDRS], Montgomery-Åsberg Depression Rating Scale, total disease duration, duration of current episode, and the number of past manic/depressive episodes). The performance of the DKI indices in identifying microstructural alterations was estimated. STATISTICAL TESTS: One-way analysis of variance (ANOVA) was used for group comparison of DKI indices. The performance of these indices in detecting microstructural alterations was determined by receiver operating characteristic (ROC) analysis. Pearson's product-moment correlation analyses were used to test the correlations of these indices with clinical variables. RESULTS: DKI revealed widespread microstructural alterations across the brain in each disorder (P < 0.05). Some were significantly different between the two disorders. Mean kurtosis (MK) in the gray matter of the right inferior parietal lobe was able to distinguish BD and MDD with an accuracy of 0.906. A strong correlation was revealed between MK in that region and YMRS in BD patients (r = -0.641, corrected P = 0.042) or 17-HDRS in MDD patients (r = -0.613, corrected P = 0.030). There were also strong correlations between a few other DKI indices and disease duration (r = -0.676 or 0.626, corrected P < 0.05). DATA CONCLUSION: DKI detected microstructural brain alterations in BD and MDD. Its indices may be useful to distinguish the two disorders or to reflect disease severity and duration. LEVEL OF EVIDENCE: 2 TECHNICAL EFFICACY STAGE: 3.
  • Differences in fractional anisotropy between the patients with schizophrenia and healthy comparison subjects.
    Daisuke Koshiyama; Masaki Fukunaga; Naohiro Okada; Kentaro Morita; Kiyotaka Nemoto; Kaori Usui; Hidenaga Yamamori; Yuka Yasuda; Michiko Fujimoto; Noriko Kudo; Hirotsugu Azechi; Yoshiyuki Watanabe; Naoki Hashimoto; Hisashi Narita; Ichiro Kusumi; Kazutaka Ohi; Takamitsu Shimada; Yuzuru Kataoka; Maeri Yamamoto; Norio Ozaki; Go Okada; Yasumasa Okamoto; Kenichiro Harada; Koji Matsuo; Hidenori Yamasue; Osamu Abe; Ryuichiro Hashimoto; Tsutomu Takahashi; Tomoki Hori; Masahito Nakataki; Toshiaki Onitsuka; Laurena Holleran; Neda Jahanshad; Theo G M van Erp; Jessica Turner; Gary Donohoe; Paul M Thompson; Kiyoto Kasai; Ryota Hashimoto
    Molecular psychiatry, 25, 4, 697, 698, Apr. 2020, [Peer-reviewed], [International Magazine]
    English, Scientific journal
  • White matter microstructural alterations across four major psychiatric disorders: mega-analysis study in 2937 individuals
    Daisuke Koshiyama; Masaki Fukunaga; Naohiro Okada; Kentaro Morita; Kiyotaka Nemoto; Kaori Usui; Hidenaga Yamamori; Yuka Yasuda; Michiko Fujimoto; Noriko Kudo; Hirotsugu Azechi; Yoshiyuki Watanabe; Naoki Hashimoto; Hisashi Narita; Ichiro Kusumi; Kazutaka Ohi; Takamitsu Shimada; Yuzuru Kataoka; Maeri Yamamoto; Norio Ozaki; Go Okada; Yasumasa Okamoto; Kenichiro Harada; Koji Matsuo; Hidenori Yamasue; Osamu Abe; Ryuichiro Hashimoto; Tsutomu Takahashi; Tomoki Hori; Masahito Nakataki; Toshiaki Onitsuka; Laurena Holleran; Neda Jahanshad; Theo G.M. van Erp; Jessica Turner; Gary Donohoe; Paul M. Thompson; Kiyoto Kasai; Ryota Hashimoto
    Molecular Psychiatry, 25, 4, 883, 895, Apr. 2020, [Peer-reviewed]
    Scientific journal
  • Apathy in Alzheimer's Disease Correlates with the Dopamine Transporter Level in the Caudate Nuclei
    Niki Udo; Naoki Hashimoto; Takuya Toyonaga; Tomoyuki Isoyama; Yuka Oyanagi; Hisashi Narita; Tohru Shiga; Shin Nakagawa; Ichiro Kusumi
    DEMENTIA AND GERIATRIC COGNITIVE DISORDERS EXTRA, 10, 2, 86, 93, 2020, [Peer-reviewed]
    English, Scientific journal
  • Tumour necrosis factor alpha blockade for non-inflammatory pain: beyond inflammation?
    N Abe; M Kato; Y Fujieda; H Narita; K K Tha; T Atsumi
    Scandinavian journal of rheumatology, 48, 6, 519, 521, Nov. 2019, [Peer-reviewed], [International Magazine]
    English
  • Depression associated with heart failure
    成田 尚
    精神科治療学, 34, 7, 793, 797, 星和書店, Jul. 2019, [Invited]
    Japanese
  • Distinctive Neuroanatomical Substrates for Depression in Bipolar Disorder versus Major Depressive Disorder
    Koji Matsuo; Kenichiro Harada; Yusuke Fujita; Yasumasa Okamoto; Miho Ota; Hisashi Narita; Benson Mwangi; Carlos A. Gutierrez; Go Okada; Masahiro Takamura; Hirotaka Yamagata; Ichiro Kusumi; Hiroshi Kunugi; Takeshi Inoue; Jair C. Soares; Shigeto Yamawaki; Yoshifumi Watanabe
    Cerebral Cortex, 29, 1, 202, 214, 2019, [Peer-reviewed]
    Scientific journal
  • Pilot Validation Study of the Japanese Translation of the Brief Negative Symptoms Scale (BNSS).
    Naoki Hashimoto; Atsuhito Toyomaki; Matsuhiko Oka; Keisuke Takanobu; Ryo Okubo; Hisashi Narita; Kan Kitagawa; Niki Udo; Tamaki Maeda; Shinya Watanabe; Yuka Oyanagi; Akane Miyazaki; Koki Ito; Ichiro Kusumi
    Neuropsychiatric disease and treatment, 15, 3511, 3518, 2019, [Peer-reviewed], [International Magazine]
    English, Scientific journal
  • Effect of Bifidobacterium breve A-1 on anxiety and depressive symptoms in schizophrenia: A proof-of-concept study
    Okubo R; Koga M; Katsumata N; Odamaki T; Matsuyama S; Oka M; Narita H; Hashimoto N; Kusumi I; Xiao J; Matsuoka YJ
    Journal of Affective Disorders, 245, 377, 385, Nov. 2018, [Peer-reviewed], [International Magazine]
    English, Scientific journal, BACKGROUND: Studies of probiotics have suggested they have a positive effect on anxiety and depressive symptoms in humans. This study investigated the effect of consuming the probiotic Bifidobacterium breve A-1 on anxiety and depressive symptoms in patients with schizophrenia and explored its effect on immune products such as cytokines and chemokines. METHODS: In this open-label single-arm study, all participants received B. breve strain A-1 (1011 cfu/day) for 4 weeks followed by 4 weeks of observation. The primary outcome was the Hospital Anxiety and Depression Scale (HADS) score. Secondary outcomes were anxiety and depressive symptoms on the Positive and Negative Syndrome Scale (PANSS), blood test findings, and fecal microbiome composition. RESULTS: Twenty-nine outpatients completed the study. HADS total score and PANSS anxiety/depression score were significantly improved at 4 weeks. Based on the criterion of a greater than 25% reduction in HADS total score at 4 weeks from baseline, there were 12 responders and 17 non-responders. Responders were found to have fewer negative symptoms, reduced intake of dairy products, and higher relative abundance of Parabacteroides in the gut microbiome than non-responders. Moreover, IL-22 and TRANCE expression was significantly increased at 4 weeks from baseline in responders but not in non-responders. LIMITATIONS: This open-label, single-arm study cannot exclude a placebo effect. CONCLUSIONS: The results suggest the potential effect of B. breve A-1 in improving anxiety and depressive symptoms in patients with schizophrenia. Further studies should investigate this effect in patients with other psychiatric conditions and assess dietary habits and the gut microbiome.
  • The effect of duration of illness and antipsychotics on subcortical volumes in schizophrenia: Analysis of 778 subjects.
    Naoki Hashimoto; Yoichi M Ito; Naohiro Okada; Hidenaga Yamamori; Yuka Yasuda; Michiko Fujimoto; Noriko Kudo; Ariyoshi Takemura; Shuraku Son; Hisashi Narita; Maeri Yamamoto; Khin Khin Tha; Asuka Katsuki; Kazutaka Ohi; Fumio Yamashita; Shinsuke Koike; Tsutomu Takahashi; Kiyotaka Nemoto; Masaki Fukunaga; Toshiaki Onitsuka; Yoshiyuki Watanabe; Hidenori Yamasue; Michio Suzuki; Kiyoto Kasai; Ichiro Kusumi; Ryota Hashimoto
    NeuroImage. Clinical, 17, 563, 569, 2018, [Peer-reviewed], [International Magazine]
    English, Scientific journal, Background: The effect of duration of illness and antipsychotic medication on the volumes of subcortical structures in schizophrenia is inconsistent among previous reports. We implemented a large sample analysis utilizing clinical data from 11 institutions in a previous meta-analysis. Methods: Imaging and clinical data of 778 schizophrenia subjects were taken from a prospective meta-analysis conducted by the COCORO consortium in Japan. The effect of duration of illness and daily dose and type of antipsychotics were assessed using the linear mixed effect model where the volumes of subcortical structures computed by FreeSurfer were used as a dependent variable and age, sex, duration of illness, daily dose of antipsychotics and intracranial volume were used as independent variables, and the type of protocol was incorporated as a random effect for intercept. The statistical significance of fixed-effect of dependent variable was assessed. Results: Daily dose of antipsychotics was positively associated with left globus pallidus volume and negatively associated with right hippocampus. It was also positively associated with laterality index of globus pallidus. Duration of illness was positively associated with bilateral globus pallidus volumes. Type of antipsychotics did not have any effect on the subcortical volumes. Discussion: A large sample size, uniform data collection methodology and robust statistical analysis are strengths of the current study. This result suggests that we need special attention to discuss about relationship between subcortical regional brain volumes and pathophysiology of schizophrenia because regional brain volumes may be affected by antipsychotic medication.
  • The mediator effect of personality traits on the relationship between childhood abuse and depressive symptoms in schizophrenia
    Ryo Okubo; Takeshi Inoue; Naoki Hashimoto; Akio Suzukawa; Hajime Tanabe; Matsuhiko Oka; Hisashi Narita; Koki Ito; Yuki Kako; Ichiro Kusumi
    PSYCHIATRY RESEARCH, 257, 126, 131, Nov. 2017, [Peer-reviewed]
    English, Scientific journal
  • Transient lesions of the splenium of the corpus callosum following rapid withdrawal of levetiracetam
    Ryo Sawagashira; Hisashi Narita; Naoki Hashimoto; Tsugiko Kurita; Shin Nakagawa; Takuya Saitoh; Ichiro Kusumi
    EPILEPTIC DISORDERS, 19, 3, 379, 382, Sep. 2017, [Peer-reviewed]
    English, Scientific journal
  • The heart of matter : Liaison psychiatry and heart transplantation
    成田 尚; 田中 輝明
    精神科治療学, 32, 2, 183, 188, 星和書店, Feb. 2017, [Invited]
    Japanese
  • Mean kurtosis alterations of cerebral white matter in patients with schizophrenia revealed by diffusion kurtosis imaging.
    Hisashi Narita; Khin K Tha; Naoki Hashimoto; Hiroyuki Hamaguchi; Shin Nakagawa; Hiroki Shirato; Ichiro Kusumi
    Progress in neuro-psychopharmacology & biological psychiatry, 71, 169, 75, Elsevier {BV}, 03 Nov. 2016, [Peer-reviewed], [Lead author, Corresponding author], [International Magazine]
    English, Scientific journal, INTRODUCTION: Diffusion kurtosis imaging can provide a better understanding of microstructural white matter (WM) changes where crossing fibers exist, compared with conventional diffusion tensor imaging. Here, we aimed to examine the differences of mean kurtosis (MK) and fractional anisotropy (FA) values between patients with schizophrenia and control subjects using voxel-based analysis (VBA). Additionally, we examined the correlation between these values and severity of clinical symptoms in patients with schizophrenia. METHODS: MK and FA values were acquired with a 3.0T scanner from 31 patients with schizophrenia and 31 age-, handedness-, and sex-matched healthy controls. VBA was used to compare the MK and FA maps of the patients with schizophrenia and healthy controls. We also performed a correlation analysis between the MK and FA values of the regions with significant differences and the positive and negative syndrome scale scores in patients with schizophrenia. RESULTS: Compared to FA values, voxels with MK decrease were more widespread across bilateral cerebral the WM of patients with schizophrenia. The MK values of left superior longitudinal fasciculus were significantly negatively correlated with the severity of positive symptoms (r=-0.451, P=0.011). There was no significant correlation between MK and FA values and other clinical variables. CONCLUSION: The diffusion kurtosis indices are suitable for evaluating altered WM structures in the human brain as they may detect white matter alterations of crossing fibers alterations of WM in schizophrenia and assess the clinical state of patients.
  • Abnormal asymmetries in subcortical brain volume in schizophrenia
    N. Okada; M. Fukunaga; F. Yamashita; D. Koshiyama; H. Yamamori; K. Ohi; Y. Yasuda; M. Fujimoto; Y. Watanabe; N. Yahata; K. Nemoto; D. P. Hibar; T. G. M. van Erp; H. Fujino; M. Isobe; S. Isomura; T. Natsubori; H. Narita; N. Hashimoto; J. Miyata; S. Koike; T. Takahashi; H. Yamasue; K. Matsuo; T. Onitsuka; T. Iidaka; Y. Kawasaki; R. Yoshimura; Y. Watanabe; M. Suzuki; J. A. Turner; M. Takeda; P. M. Thompson; N. Ozaki; K. Kasai; R. Hashimoto
    MOLECULAR PSYCHIATRY, 21, 10, 1460, 1466, Oct. 2016, [Peer-reviewed]
    English, Scientific journal
  • Characteristics of Diffusional Kurtosis in Chronic Ischemia of Adult Moyamoya Disease: Comparing Diffusional Kurtosis and Diffusion Tensor Imaging
    K. Kazumata; K. K. Tha; H. Narita; Y. M. Ito; H. Shichinohe; M. Ito; H. Uchino; T. Abumiya
    AMERICAN JOURNAL OF NEURORADIOLOGY, 37, 8, 1432, 1439, Aug. 2016, [Peer-reviewed]
    English, Scientific journal
  • Distinct and shared morphometric biomarkers of depressed individuals with bipolar disorder and major depressive disorder
    Matsuo Koji; Fujita Yusuke; Harada Kenichiro; Inoue Takeshi; Kunugi Hiroshi; Kusumi Ichiro; Narita Hisashi; Okada Go; Okamoto Yasumasa; Ota Miho; Takamura Masahiro; Watanabe Yoshifumi; Yamagata Hirotaka; Yamawaki Shigeto
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 19, 62, 63, Jun. 2016, [Peer-reviewed]
  • Investigating Brain Network Characteristics Interrupted by Covert White Matter Injury in Patients with Moyamoya Disease: Insights from Graph Theoretical Analysis
    Ken Kazumata; Khin Khin Tha; Hisashi Narita; Hideo Shichinohe; Masaki Ito; Haruto Uchino; Takeo Abumiya
    WORLD NEUROSURGERY, 89, 654, +, May 2016, [Peer-reviewed]
    English, Scientific journal
  • A Case of Dilated Cardiomyopathy after 17 Years of Clozapine Treatment
    大久保亮; 橋本直樹; 草地麻実; 成田尚; 久住一郎
    精神神経学雑誌, 118, 10, 735, 743, 日本精神神経学会, 2016, [Peer-reviewed]
    Japanese
  • Simple Pulmonary Eosinophilia Associated With Clozapine Treatment
    Naoki Hashimoto; Tamaki Maeda; Ryo Okubo; Hisashi Narita; Ichiro Kusumi
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 35, 1, 99, 101, Feb. 2015, [Peer-reviewed]
    English
  • Chronic Ischemia Alters Brain Microstructural Integrity and Cognitive Performance in Adult Moyamoya Disease
    Ken Kazumata; Khin Khin Tha; Hisashi Narita; Ichiro Kusumi; Hideo Shichinohe; Masaki Ito; Naoki Nakayama; Kiyohiro Houkin
    STROKE, 46, 2, 354, 360, Feb. 2015, [Peer-reviewed]
    English, Scientific journal
  • Chronic Ischemia Alters Brain Microstructural Integrity and Cognitive Performance in Adult Moyamoya Disease
    Kazumata Ken; Tha Khin Khin; Narita Hisashi
    Stroke : journal of the American Heart Association, 10, 1, 10, 16, Blackwell Publishing, 2015, [Peer-reviewed]
    Japanese
  • Clozapine誘発性無顆粒球症を発症した慢性期統合失調症の1例
    橋本直樹; 小山司; 近藤健; 斉藤拓; 大久保亮; 成田尚; 久住一郎
    精神神経学雑誌, 116, 12, 1042, 25 Dec. 2014, [Peer-reviewed]
    Japanese
  • Absent activation in medial prefrontal cortex and temporoparietal junction but not superior temporal sulcus during the perception of biological motion in schizophrenia: A functional MRI study
    Naoki Hashimoto; Atsuhito Toyomaki; Masahiro Hirai; Tamaki Miyamoto; Hisashi Narita; Ryo Okubo; Ichiro Kusumi
    Neuropsychiatric Disease and Treatment, 10, 2221, 2230, 17 Nov. 2014, [Peer-reviewed]
    English, Scientific journal
  • 高次脳機能障害患者に維持透析導入の検討を要した1例
    磯山 友幸; 成田 尚; 林下 善行; 賀古 勇輝; 久住 一郎
    精神神経学雑誌, 115, 10, 1088, 1088, (公社)日本精神神経学会, Oct. 2013
    Japanese
  • 高次脳機能障害患者に維持透析導入の検討を要した一例
    磯山 友幸; 成田 尚; 林下 善行; 賀古 勇輝; 久住 一郎
    精神神経学雑誌, 2013特別, S, 522, (公社)日本精神神経学会, May 2013
    Japanese
  • 悪性症候群について
    成田尚; 菅原麻里衣; 三戸法和; 三上敦大; 本間次郎; 高田秀樹
    市立室蘭総合病院医誌, 35, 1, 53, 31 Oct. 2010
    Japanese
  • MRI及び脳波検査で経過を追ったクロイツフェルト・ヤコブ病(CJD)の1例
    三宅麻里衣; 成田尚; 三戸法和; 三上敦大; 本間次郎; 高田秀樹; 吉田悟
    市立室蘭総合病院医誌, 35, 1, 39, 43, 市立室蘭総合病院, 31 Oct. 2010
    Japanese, プリオン病の中でも、孤発性クロイツフェルト・ヤコブ病が大部分を占める。多くは初老期に発症し、認知症症状・ミオクローヌス・周期性同期性放電(PSD)の3徴を呈し、早期に無言無動となる。当科患者において、初期より急速に進行する認知症症状、MRI DWI で左大脳皮質・基底核に限局した高信号、脳波では徐波から周期性一側性てんかん型放電(PLEDs)、PSDと、孤発性クロイツフェルト・ヤコブ病に典型的な所見を認め、診断に寄与したと考えられた。
■ Other Activities and Achievements
  • Investigation of the Relationship Between Late-Life Mood Symptoms and CSF Phosphorylated Tau in Cognitive Decline
    Takashi Ozaki; Naoki Hashimoto; Niki Udo; Shizuka Mito; Hisashi Narita; Shin Nakagawa; Ichiro Kusum; Takahiro A. Kato, INTERNATIONAL PSYCHOGERIATRICS, 37, 5, Nov. 2025
    English, Summary international conference
  • 心臓移植医療における精神科医の役割-心臓移植医,当事者の方との対話-
    杉田尚子; 中西健二; 西村勝治; 佐藤琢真; 成田尚; 疇地道代; 木村宏之; 桂川修一; 浦和愛子; 岸辰一; 庵地雄太, 総合病院精神医学, 37, Supplement, 2025
  • 統合失調症の併存により薬物療法に難渋した若年性パーキンソン病例
    大槻幸造; 大槻幸造; 澤頭亮; 白井慎一; 江口克紀; 中村悠一; 成田尚; 橋本直樹, 総合病院精神医学, 36, Supplement, 2024
  • 当院における統合失調症入院患者の抗精神病薬処方調査
    梅津弘樹; 中村悠一; 成田尚, 精神神経学雑誌, 120, 8, 2018
  • 抗精神病薬が海馬,淡蒼球体積に与える影響:国内大規模多施設共同研究から
    橋本直樹; 伊藤陽一; 岡田直大; 山森英長; 安田由華; 藤本美智子; 工藤紀子; 竹村有由; 孫樹洛; 成田尚; 山本真江里; タ キンキン; 香月あすか; 大井一高; 山下典生; 小池進介; 高橋努; 根本清貴; 福永雅喜; 鬼塚俊明; 渡邉嘉之; 笠井清登; 鈴木道雄; 久住一郎; 橋本亮太; 橋本亮太, 統合失調症研究, 8, 1, 2018
  • Levetiracetamの急激な中止により引き起こされた一過性脳梁膨大部病変の一例
    澤頭 亮; 成田 尚; 橋本 直樹; 栗田 紹子; 中川 伸; 久住 一郎, 日本神経精神薬理学会年会プログラム・抄録集, 46回, 163, 163, Jul. 2016
    (一社)日本神経精神薬理学会, Japanese
  • 統合失調症患者の抑うつ症状に幼少期ストレス・気質性格が与える影響に関する検討
    大久保亮; 井上猛; 鈴川晶夫; 中井幸衛; 豊巻敦人; 草地麻実; 梅津弘樹; 中村悠一; 岡松彦; 石井純; 成田尚; 伊藤侯輝; 賀古勇輝; 久住一郎, 日本精神科診断学会プログラム・抄録集, 36th, 2016
  • ENIGMA-SZJ:統合失調症の皮質下体積のメタアナリシス
    岡田 直大; 福永 雅喜; 山下 典生; 越山 太輔; 山森 英長; 大井 一高; 安田 由華; 藤本 美智子; 渡邉 嘉之; 八幡 憲明; 根本 清貴; 磯部 昌憲; 磯村 周一; 夏堀 龍暢; 成田 尚; 橋本 直樹; 宮田 淳; 小池 進介; 高橋 努; 山末 英典; 松尾 幸治; 鬼塚 俊明; 飯高 哲也; 吉村 玲児; 渡邉 義文; 鈴木 道雄; 武田 雅俊; 尾崎 紀夫; 笠井 清登; 橋本 亮太, 日本生物学的精神医学会・日本神経精神薬理学会合同年会プログラム・抄録集, 37回・45回, 204, 204, Sep. 2015
    日本生物学的精神医学会・日本神経精神薬理学会, Japanese
  • 拡散尖度画像(DKI)を用いた気分障害の病態研究
    中川 伸; Tha Khin Khin; 成田 学; 秋谷 絵理; 成田 尚; 仲唐 安哉; 亀山 梨絵; 若槻 百美; 北川 寛; 井上 猛; 久住 一郎, 先進医薬研究振興財団研究成果報告集, 2014年度, 30, 31, Mar. 2015
    (公財)先進医薬研究振興財団, Japanese
■ Books and other publications
  • 心不全(第3版)第Ⅳ巻
    成田尚, XVIII.心不全の併存症―病態、治療― 13.うつ・不安
    Dec. 2026, [Contributor]
  • サイコカーディオロジー
    成田尚, 循環器疾患治療薬が精神障害に与える影響と注意点 (精神科医の視点から)
    Nov. 2026, [Contributor]
  • 精神科リエゾン・エッセンシャルズ すべての医療者が学べる基礎・応用・エキスパートの視点
    サイコカーディオロジー
    Nov. 2026, [Contributor]
  • ECT実践のためのAPAタスクフォースレポート3rd推奨ガイド
    第8章 留意すべき患者群におけるECTの使用
    Oct. 2026
  • 研修医のための精神科ハンドブック = Psychiatric handbook for residents
    日本精神神経学会卒前医学教育・卒後臨床研修委員会; 日本精神神経学会, 入院(急性期、隔離・拘束などを含む実践的側面)
    医学書院, Jun. 2025, 9784260061575, x, 154p, Japanese, [Contributor]
  • 心臓移植後診療の指針
    12章 移植後のメンタルケア
    Jul. 2024, 9784815731106, [Contributor]
  • 地域精神医療リエゾン精神医療精神科救急医療 = Community psychiatry consultation-liaison psychiatry emergency psychiatry
    斎藤, 正彦, サイコカーディオロジー
    中山書店, Jun. 2022, 9784521748276, xvii, 525p, Japanese, [Contributor]
■ Lectures, oral presentations, etc.
  • 精神神経科専門医は、ここに着目して、治療を見極めています!
    成田尚
    第2回サイコカーディオロジー学会, 19 Dec. 2026, Nominated symposium
    19 Dec. 2026 - 19 Dec. 2026, [Invited]
  • DPAT
    成田尚
    北海道の災害医療・保健・福祉を考えるシンポジウム ~地域で二次的健康被害をふせぐ~, 14 Oct. 2026, Nominated symposium
    14 Oct. 2026 - 14 Oct. 2026, [Invited]
  • 依存症併存患者における、治療アドヒアランス向上に向けた精神科アプローチの重要性について
    成田尚
    第74 回日本心臓病学会学術集会, 13 Sep. 2026, Nominated symposium
    11 Sep. 2026 - 13 Sep. 2026, [Invited]
  • 君はカタトニアを見たことがあるか?ー適切な診断と治療を自分のものにー
    安田和幸; 田村赳紘; 成田 尚; 坂寄 健; 内沼虹衣菜; 吉岡大祐; 清水 敏幸; 八田 耕太郎
    第38回日本総合病院精神医学会学術総会, 21 Nov. 2025, Public symposium
    21 Nov. 2025 - 22 Nov. 2025, [Invited]
  • 心臓移植医療における精神科医の役割 -心臓移植医、当事者の方との対話- 症例提示
    成田尚
    第38回日本総合病院精神医学会学術総会, 21 Nov. 2025, Japanese, Nominated symposium
    21 Nov. 2025 - 22 Nov. 2025, [Invited]
  • Cardiovascular adverse reactions associated with escitalopram in patients with underlying cardiovascular diseases: a systematic review and meta-analysis
    Hisashi Narita,Kenichi Kimura
    27TH ANNUAL CONFERENCE OF THE INTERNATIONAL SOCIETY FOR BIPOLAR DISORDERS, 18 Sep. 2025, English, Poster presentation
    16 Sep. 2025 - 19 Sep. 2025
  • サイコカーディオロジーのすゝめ
    成田尚
    第121回日本精神神経学会学術総会, 20 Jun. 2025, Nominated symposium
    19 Jun. 2025 - 21 Jun. 2025, [Invited]
  • DPAT(災害派遣精神医療チーム)
    成田 尚
    令和6年度北海道医師会救急医療対策部会全体会議, 26 Jan. 2025, Invited oral presentation
    26 Jan. 2025 - 26 Jan. 2025, [Invited]
  • 心不全とうつ病
    成田尚
    精神神経科・循環器内科連携検討会, 19 Dec. 2024
    19 Dec. 2024 - 19 Dec. 2024, [Invited]
  • サイコカーディオロジーのすゝめ
    成田尚
    第37回日本総合病院精神医学会学術総会, 30 Nov. 2024, Nominated symposium
    29 Nov. 2024 - 30 Nov. 2024, [Invited]
  • ECTの症例グループディスカッション
    安田和幸; 川島啓嗣; 栗本直樹; 田村赳紘; 坪井貴嗣; 成田 尚; 坂寄 健; 内沼虹衣菜; 青木宣篤; 吉岡大祐
    第37回日本総合病院精神医学会学術総会, 29 Nov. 2024, Public symposium
    29 Nov. 2024 - 30 Nov. 2024, [Invited]
  • 北海道大学病院による北の大地での取り組みについて
    成田尚
    第37回日本総合病院精神医学会学術総会, 29 Nov. 2024, Nominated symposium
    29 Nov. 2024 - 30 Nov. 2024, [Invited]
  • 北海道におけるDPATの現状と課題 ~災害時に北海道の精神科は、何ができるのか~
    成田尚
    日精協北海道支部看護部長会災害対策研修, 05 Oct. 2024, Public discourse
    05 Oct. 2024 - 05 Oct. 2024, [Invited]
  • 北海道における ECTの課題と対策
    成田尚
    第120回日本精神神経学会学術総会, 21 Jun. 2024, Nominated symposium
    20 Jun. 2024 - 22 Jun. 2024, 27301053, [Invited]
  • 重症心不全の心移植と緩和ケア
    成田尚
    第120回日本精神神経学会学術総会, 21 Jun. 2024, Nominated symposium
    20 Jun. 2024 - 22 Jun. 2024, 27301053, [Invited]
  • ECTのリスクマネジメントと薬剤
    成田尚
    第33回日本臨床精神神経薬理学会学術集会, 26 May 2024, Nominated symposium
    24 May 2024 - 26 May 2024, [Invited]
  • 電気けいれん療法症例グループディスカッション
    諏訪 太朗; 嶽北 佳輝; 栗本 直樹; 坂寄 健; 田村 赳紘; 坪井 貴嗣; 安田 和幸; 川島 啓嗣; 成田 尚; 坂寄 健; 内沼虹衣菜
    第36回日本総合病院精神医学会学術総会, 18 Nov. 2023, Public symposium
    17 Nov. 2023 - 18 Nov. 2023, [Invited]
  • 心血管系基礎疾患を有する患者へのエスシタロプラム投与:系統的レビューとメタ解 析
    木村 憲一; 成田 尚; 今井 必生; 秋山 久; 石川 修平; 澤頭 亮; 磯山 友幸; 野原万梨子; 川村 路代; 河野由香里; 齊藤 卓弥; 久住 一郎
    第36回日本総合病院精神医学会総会, 17 Nov. 2023, Poster presentation
  • 多施設共同研究によるdrug-freeの統合失調症患者における 大脳皮質構造への疾患の効果の検討
    第45回日本生物学的精神医学会年会, 07 Nov. 2023
    06 Nov. 2023 - 07 Nov. 2023
  • 児童思春期発症のうつ病の多施設大規模データによる大脳皮質構造解析
    第45回日本生物学的精神医学会年会, 07 Nov. 2023
  • 生体移植ドナーの精神的・身体的サポート 生体肝移植ドナーの併存精神疾患と精神科連携
    木村宏之; 杉田尚子; 大橋綾子; 成田尚; 藤澤大介; 岡田剛史; 松本洋輔; 岸辰一; 川㟢弘詔; 西村勝治; 小倉靖弘; 池田匡志
    日本移植学会総会, 22 Sep. 2023
  • クロザピン誘発発作に対する抗痙攣薬の使用 統合失調症患者における後ろ向き研究(Use of Anti-Seizure Medications for Clozapine-Induced Seizures: A Retrospective Study in Patients with Schizophrenia)
    堀之内 徹; 中村 悠一; 石川 修平; 橋本 直樹; 成田 尚; 三井 信幸; 賀古 勇輝; 久住 一郎
    てんかん研究, Sep. 2023, (一社)日本てんかん学会, English
    Sep. 2023 - Sep. 2023
  • 精神科(病院)におけるクラスター対応 ~災害対応としてのDPATとの異同を含め~
    成田尚
    第61回 全国自治体病院学会, 01 Sep. 2023, Nominated symposium
    31 Aug. 2023 - 01 Sep. 2023, [Invited]
  • 身体拘束と深部静脈血栓症
    成田尚
    第119回日本精神神経学会学術総会, 23 Jun. 2023, Nominated symposium
    27301053, [Invited]
  • クロザピンによる過活動膀胱の発現メカニズムの解明と臨床的指標の探索
    可児 涼真; 成田 尚; 石川 修平; 久住 一郎
    精神神経学雑誌, Jun. 2023, (公社)日本精神神経学会, Japanese
    Jun. 2023 - Jun. 2023
  • Mega-analysis of differentiation of schizophrenia using structural MRI with consideration of scanner differences.
    Hashimoto N; Nemoto K; Fukunaga M; Matsumoto J; Miura K; Okada N; Morita K; Koshiyama D; Ohi K; Takahashi T; Koeda M; Yamamori H; Fujimoto M; Yasuda Y; Hasegawa N; Ito S; Narita H; Yokoyama S; Mishima R; Kawashima T; Kobayashi Y; Sasabayashi D; Harada K; Yamamoto M; Hirano Y; Itahashi T; Nakataki R; Hashimoto R; Tha KK; Koike S; Matsubara T; Okada G; Yoshimura R; Abe O; Onitsuka; Watanabe Y; Matsuo K; Yamasue H; Okamoto Y; Suzuki M; Ozaki N; Kasai K; Hashimoto R
    2023 Congress of the Schizophrenia International Research Society (SIRS)
    11 May 2023 - 15 May 2023
  • 脳構造画像を用いた統合失調症らしさのメガアナライシス
    橋本直樹; 根本清貴; 福永雅喜; 松本純弥; 三浦健一郎; 岡田直大; 森田健太郎; 越山太輔; 大井一高; 高橋努肥; 田道彦; 山森英長; 藤本美智子; 安田由華; 長谷川尚美; 伊藤颯姫; 成田尚; 横山仁史; 三嶋亮; 河島孝彦; 小林祐子; 笹林大樹; 原田健一郎; 山本真江里; 平野羊嗣; 板橋貴史; 中瀧理仁; 橋本龍一郎; タ キンキン; 小池進介; 松原敏郎; 岡田剛; 吉村玲児; 阿部修; 鬼塚俊明; 渡邊嘉之; 松尾幸治; 山末英典; 岡本泰昌; 鈴木道雄; 尾崎紀夫; 笠井清登; 橋本亮太
    第17回日本統合失調症学会, 25 Mar. 2023
    25 Mar. 2023 - 26 Mar. 2023
  • Validity and Reliability of a Palliative Care Needs Assessment Tool in Japanese Patients with Heart Failure
    Daishiro Tatsuta, MDa; Takuma Sato; MD, PhDa; Toshiyuki Nagai; MD, PhDa; Jiro Koya, MD; Kotaro Nishino, MD; Seiichiro Naito, MD; Yoshifumi Mizuguchi; MD, PhDa; Taro Temma; MD, PhDa; Kiwamu Kamiya; MD, PhDa; Hisashi Narita MD; PhDb; Kenkichi Tsuruga MD; PhDc; Toshihisa Anzai; MD, PhDa
    American Heart Association, 2023, Oral presentation
  • 統合失調症・双極性障害・うつ病・自閉スペクトラム症の 多施設大規模データによる疾患横断的な大脳皮質構造の類似度の解析
    松本 純弥; 福永 雅喜; 三浦 健一郎; 根本 清貴; 岡田 直大; 橋本 直樹; 森田 健太郎; 越山 太輔; 大井 一高; 橋; 肥田 道; 山森 英; 藤本 美智; 安田 由華; 長谷川 尚美; 伊藤 颯姫; 成田 尚; 横山 仁; 嶋; 河島 孝; 小林 祐; 笹林 大; 原田 健一; 山本 真江; 平野 羊; 板橋 貴; 中瀧 理; 橋本 龍一; タ キンキン; 小池 進; 松原 敏; 田; 吉村 玲; 部; 鬼塚 俊; 渡邊 嘉; 松尾 幸; 山末 英; 岡本 泰; 鈴木 道; 尾崎 紀; 笠井 清; 橋本 亮
    第44回日本生物学的精神医学会年会、第32回日本臨床精神神経薬理学会年会、第52回日本神経精神薬理学会年会、第6回日本精神薬学会総会・学術集会 合同年会, 04 Nov. 2022, Poster presentation
    04 Nov. 2022 - 06 Nov. 2022
  • 危機的状況について考える ―多職種・連携・対応―
    井上真一郎; 井上敦子; 大橋綾子; 岸辰一; 桂川修一; 小林清香; 成田尚; 浦和愛子; 西村勝治
    第35回日本総合病院精神医学会学術総会, 28 Oct. 2022, Nominated symposium
    [Invited]
  • 電気けいれん療法症例グループディスカッション-カタトニアの治療戦略
    諏訪 太朗; 嶽北 佳輝; 栗本 直樹; 坂寄 健; 飯田 仁志; 田村 赳紘; 坪井 貴嗣; 安田 和幸; 川島 啓嗣; 成田 尚; 坂寄 健; 内沼虹衣菜
    第35回日本総合病院精神医学会学術総会, 28 Oct. 2022, Public symposium
    [Invited]
  • 北海道大学病院 精神科神経科病棟におけるDVT予防治療への取り組みについて
    成田尚
    第30回日本精神科救急学会学術総会, 30 Sep. 2022
    30 Sep. 2022 - 01 Oct. 2022, [Invited]
  • 末期心不全患者の難治性不整脈に対するICD治療機能停止(deactivation)の検討を多職種で行った一例
    甲谷次郎; 佐藤琢真; 立田大志郎; 西野広太郎; 小林雄太; 成田 尚; 敦賀健吉; 青陽千果; 池田陽子; 小島尚子; 古山勇気; 小野田紘子; 加藤美香; 永井利幸; 安斉俊久
    第70回 日本心臓病学会学術集会 ハートチームによる医療の部門, Oral presentation
    23 Sep. 2022 - 25 Sep. 2022
  • 精神疾患別の自殺企図患者の急性期予後
    土田 拓見; 高橋 正樹; 成田 尚; 水柿 明日美; 和田 剛志
    日本精神科救急学会学術総会プログラム・抄録集, Sep. 2022, (一社)日本精神科救急学会, Japanese
    Sep. 2022 - Sep. 2022
  • 大学病院精神科作業療法の現場におけるCOVID-19に対する感染対策の現状と課題について
    西川 玲; 富永; 武井; 佐藤 なるみ; 大澤 恵; 三井; 成田; 池田; 生駒
    日本リハビリテーション医学会北海道地方会, 25 Apr. 2022
  • 電気けいれん療法(ECT)の症例グループディスカッションと右片側刺激ハンズオンセミナー
    第34回日本総合病院精神医学会学術総会, 20 Nov. 2021, Nominated symposium
    [Invited]
  • Cortical structural mega-analysis across four major psychiatric disorders in 5432 individuals.
    7th Congress of AsCNP 2021 (AsianCollege of Neuropsychopharmacology 2021), Virtural Congress,, 22 Oct. 2021, English, Poster presentation
  • Covid-19下でのECT技法
    第117回日本精神神経学会学術総会, 19 Sep. 2021, Nominated symposium
    19 Sep. 2021 - 21 Sep. 2021, [Invited]
  • 本邦のCOVID-19にまつわる不安
    第13回日本不安症学会学術大会, 22 May 2021, Nominated symposium
    22 May 2021 - 21 Jun. 2021, 27301053, [Invited]
  • 循環器疾患患者のこころの問題にどう向き合うか?(緩和ケアも含めて) 当院における心不全緩和ケアチームの立ち上げと現状
    阿部 隆宏; 佐藤 琢真; 加藤 美香; 笠谷 美鈴; 成田 尚; 福澤 宏之; 片山 真育; 池田 陽子; 小島 尚子; 杉本 由佳; 永井 利幸; 安斉 俊久
    日本循環器学会学術集会抄録集, Mar. 2021, (一社)日本循環器学会, Japanese
    Mar. 2021 - Mar. 2021
  • Paliperidoneで好中球減少をきたした統合失調症の1例
    今本真衣子; 大柳有加; 磯山友幸; 石川修平; 宇土仁木; 成田尚; 久住一郎
    精神神経学雑誌, 2021
    2021 - 2021
  • 生体肝移植ドナーに併存する精神疾患
    木村宏之; 岸辰一; 亀井秀弥; 尾崎紀夫; 杉田尚子; 野間俊一; 大橋綾子; 光安博志; 成田尚; 田中輝明; 藤澤大介; 岡田剛史; 川㟢弘詔; 西村勝治; 小倉靖弘; 尾崎紀夫
    日本肝移植学会, 25 Dec. 2020
  • 災害時における精神医学の役割
    日本精神神経学会精神科専門医制度 生涯教育研修会, 06 Dec. 2020, Public discourse
    06 Dec. 2020 - 06 Dec. 2020, 27301053, [Invited]
  • Resting-State Functional Connectivity of Pain Processing Brain Region Associated with Therapeutic Response to Biologics in Rheumatoid Arthritis and Spondyloarthritis
    Nobuya Abe; Yuichiro Fujieda; Kuniyuki Aso; Kohei Karino; Michihito Kono; Hisashi Narita; Masaru Kato; Kenji Oku; Tha Khin Khin; Olga Amengual; Shinsuke Yasuda; Tatsuya Atsumi
    2019 ACR/ARP Annual Meeting, 06 Nov. 2019, English, Poster presentation
    [International presentation]
  • 急性期医療における総合病院精神科医の役割 循環器領域を中心に
    成田 尚
    日本医療・病院管理学会誌, Oct. 2019, Japanese, Nominated symposium
    [Invited]
  • 精神科診療におけるアミロイドPETの活用―FTDとADの鑑別にアミロイドPETが有効だった1例―
    内藤大; 宇土仁木; 服部直也; 大柳有加; 北川寛; 成田尚; 久住一郎
    精神神経学雑誌, 25 Aug. 2019, Japanese
  • PHQ‐9およびSF‐8の調査結果から考察する肝移植ドナーの長期予後について
    成田尚; 黒鳥偉作; 大柳有加; 高信径介; 渡辺晋也; 宇土仁木; 前田珠希; 岡松彦; 北川寛; 久住一郎
    日本精神神経学会総会プログラム・抄録集, 22 Jun. 2019, Japanese, Poster presentation
    [Domestic Conference]
  • 日本語版PANSSの信頼性、妥当性評価
    橋本 直樹; 岡 松彦; 高信 径介; 成田 尚; 北川 寛; 宇土 仁木; 前田 珠希; 渡辺 晋也; 大柳 有加; 宮崎 茜; 伊藤 侯輝; 久住 一郎
    精神神経学雑誌, Jun. 2019, Japanese
  • Alzheimer型認知症のBPSDと脳内Dopamine神経系の関連
    宇土仁木; 橋本直樹; 中川伸; 豊永拓哉; 大柳有加; 北川寛; 成田尚; 久住一郎
    日本精神神経学会総会プログラム・抄録集, Jun. 2019, Japanese
  • MianserinからMirtazapineへの置換中にセロトニン症候群が生じた一例
    黒鳥偉作; 橋本直樹; 石川修平; 成田尚; 久住一郎
    日本精神神経学会総会プログラム・抄録集, Jun. 2019, Japanese
  • Differences in Brain Microstructural Alterations between Bipolar and Major Depression Revealed by Diffusion Kurtosis Imaging
    Daisuke Sawamura; Khin Tha; Naoki Hashimoto; Hisashi Narita; Shin Nakagawa; Hiroki Shirato
    ISMRM 27TH ANNUAL MEETING & EXHIBITION, May 2019, English, Poster presentation
    [International presentation]
  • 日本語版BNSSの信頼性,妥当性評価
    橋本直樹; 岡松彦; 高信径介; 成田尚; 北川寛; 宇土仁木; 前田珠希; 渡辺晋也; 大柳有加; 宮崎茜; 伊藤侯輝; 久住一郎
    統合失調症研究, Mar. 2019, Japanese
  • 統合失調症の不安抑うつ症状に対するBifidobacterium breve A1の効果に関する検討:A proof‐of‐concept study
    大久保亮; 大久保亮; 古賀農人; 勝又紀子; 小田巻敏孝; 松山詩菜; 岡松彦; 成田尚; 橋本直樹; 久住一郎; 松岡豊
    統合失調症研究, Mar. 2019, Japanese
  • 統合失調症の不安抑うつ症状に対するBifidobacterium breve A1の効果に関する検討:A proof-of-concept study
    大久保亮; 大久保亮; 古賀農人; 勝又紀子; 小田巻敏孝; 松山詩菜; 岡松彦; 成田尚; 橋本直樹; 久住一郎; 松岡豊
    統合失調症研究, 2019
    2019 - 2019
  • 心移植・VAD治療におけるAdvance Care Planning実践の検討
    加藤美香; 櫛引勝年; 山本真由美; 中野政子; 成田尚; 福島新; 加藤裕貴; 大岡智学; 安斉俊久; 松居喜郎
    日本心臓移植研究会学術集会プログラム・抄録集(Web), Dec. 2018, Japanese
  • PHQ-9およびSF-8の調査結果から考察する肝移植ドナーの長期予後について
    黒鳥 偉作; 成田 尚; 大柳 有加; 高信 径介; 渡辺 晋也; 宇土 仁木; 前田 珠希; 岡 松彦; 北川 寛; 久住 一郎
    総合病院精神医学, 30 Nov. 2018, Japanese, Poster presentation
    [Domestic Conference]
  • Bifidobacterium breve AIによる統合失調症の不安抑うつ症状に対する効果の検討
    大久保 亮; 古賀 農人; 勝又 紀子; 小田巻 敏孝; 松山 詩菜; 岡 松彦; 成田 尚; 橋本 直樹; 久住 一郎; 清水 金忠
    総合病院精神医学, Nov. 2018, Japanese
  • 精神疾患併存が肝移植レシピエントの生存に与える影響
    木村宏之; 岸辰一; 岡田剛史; 成田尚; 田中輝明; 町野彰彦; 松本洋輔; 藤澤大介; 大橋綾子; 光安博志; 野間俊一; 西村勝治; 川嵜弘詔; 小倉靖弘; 尾崎紀夫
    日本移植学会総会プログラム抄録集, Sep. 2018, Japanese
  • 当院における統合失調症入院患者の抗精神病薬処方調査
    梅津弘樹; 中村悠一; 成田尚
    精神神経学雑誌, 25 Aug. 2018, Japanese
  • 抗精神病薬が海馬,淡蒼球体積に与える影響:国内大規模多施設共同研究から
    橋本直樹; 伊藤陽一; 岡田直大; 山森英長; 安田由華; 藤本美智子; 工藤紀子; 竹村有由; 孫樹洛; 成田尚; 山本真江里; タ キンキン; 香月あすか; 大井一高; 山下典生; 小池進介; 高橋努; 根本清貴; 福永雅喜; 鬼塚俊明; 渡邉嘉之; 笠井清登; 鈴木道雄; 久住一郎; 橋本亮太; 橋本亮太
    統合失調症研究, 01 Mar. 2018, Japanese
  • 虐待,ネグレクトなどの幼少期ストレスが統合失調症に与える影響に関する人格傾向の媒介効果
    大久保亮; 大久保亮; 井上猛; 三井信幸; 橋本直樹; 田辺肇; 岡松彦; 成田尚; 伊藤候輝; 賀古勇輝; 久住一郎; 松岡豊
    日本疫学会学術総会講演集(Web), 01 Feb. 2018, Japanese
  • 炭酸リチウムと抗精神病薬が感情障害患者の皮質下脳体積に与える影響についての検討
    橋本直樹; 成田尚; 岡田直大; 福永雅喜; 橋本亮太; 橋本亮太; 久住一郎
    日本うつ病学会総会プログラム・抄録集, 2018, Japanese
  • Levetiracetamの急激な中止により引き起こされた一過性脳梁膨大部病変の一例
    澤頭 亮; 成田 尚; 橋本 直樹; 栗田 紹子; 中川 伸; 久住 一郎
    日本神経精神薬理学会年会プログラム・抄録集, Jul. 2016, Japanese
  • 臓器移植と精神医学の新たな展開 移植医療と精神疾患 心臓移植における精神医学的問題
    成田 尚; 田中 輝明
    精神神経学雑誌, Jun. 2016, Japanese, Nominated symposium
    [Invited]
  • 拡散尖度画像を用いた統合失調症の白質構造変化について
    成田尚; 橋本直樹; 伊藤候輝; 大久保亮; 久住一郎
    日本生物学的精神医学会(Web), 2016, Japanese
  • 心臓移植における精神医学的問題
    成田尚; 田中輝明
    日本精神神経学会総会プログラム・抄録集, 2016, Japanese, Nominated symposium
    [Invited]
  • 統合失調症患者の抑うつ症状に幼少期ストレス・気質性格が与える影響に関する検討
    大久保亮; 井上猛; 鈴川晶夫; 中井幸衛; 豊巻敦人; 草地麻実; 梅津弘樹; 中村悠一; 岡松彦; 石井純; 成田尚; 伊藤侯輝; 賀古勇輝; 久住一郎
    日本精神科診断学会プログラム・抄録集, 2016, Japanese
  • 気分障害における報酬予測に対する腹側線条体の活動
    若槻百美; 橋本直樹; 小倉有紀子; 中井幸衛; 宮本環; 北川寛; 大久保亮; 豊島邦義; 亀山梨絵; 成田尚; 藤井泰; 仲唐安哉; 伊藤侯輝; 賀古勇輝; 朝倉聡; 中川伸; 井上猛; 久住一郎
    日本生物学的精神医学会(Web), 2016, Japanese
  • ENIGMA-SZJ:統合失調症の皮質下体積のメタアナリシス
    岡田 直大; 福永 雅喜; 山下 典生; 越山 太輔; 山森 英長; 大井 一高; 安田 由華; 藤本 美智子; 渡邉 嘉之; 八幡 憲明; 根本 清貴; 磯部 昌憲; 磯村 周一; 夏堀 龍暢; 成田 尚; 橋本 直樹; 宮田 淳; 小池 進介; 高橋 努; 山末 英典; 松尾 幸治; 鬼塚 俊明; 飯高 哲也; 吉村 玲児; 渡邉 義文; 鈴木 道雄; 武田 雅俊; 尾崎 紀夫; 笠井 清登; 橋本 亮太
    日本生物学的精神医学会・日本神経精神薬理学会合同年会プログラム・抄録集, Sep. 2015, 日本生物学的精神医学会・日本神経精神薬理学会, Japanese
    Sep. 2015 - Sep. 2015
  • ENIGMA‐SZJ:統合失調症の皮質下体積のメタアナリシス
    岡田直大; 福永雅喜; 山下典生; 越山太輔; 山森英長; 大井一高; 安田由華; 藤本美智子; 渡邉嘉之; 八幡憲明; 根本清貴; 磯部昌憲; 磯村周一; 夏堀龍暢; 成田尚; 橋本直樹; 宮田淳; 小池進介; 高橋努; 山末英典; 松尾幸治; 鬼塚俊明; 飯高哲也; 吉村玲児; 渡邉義文; 鈴木道雄; 武田雅俊; 尾崎紀夫; 笠井清登; 橋本亮太; 橋本亮太
    日本神経精神薬理学会プログラム・抄録集, Sep. 2015, Japanese
  • 統合失調症患者におけるJSQLSと脳灰白質体積の縦断的変化の相関について
    成田 尚; 橋本 直樹; 大久保 亮; 伊藤 候輝; 久住 一郎
    日本生物学的精神医学会・日本神経精神薬理学会合同年会プログラム・抄録集, Sep. 2015, Japanese
  • 拡散尖度画像(DKI)を用いた気分障害の病態研究
    中川伸; THA Khin Khin; 成田学; 秋谷絵理; 成田尚; 仲唐安哉; 亀山梨絵; 若槻百美; 北川寛; 井上猛; 久住一郎
    先進医薬研究振興財団 2014年度 研究成果報告集, 2015, Japanese
  • Diffusion Kurtosis Imagingによる統合失調症患者の白質病変の評価
    成田尚; タ キンキン; 賀古勇輝; 大久保亮; 伊藤候輝; 工藤興亮; 久住一郎
    日本精神科診断学会プログラム・抄録集, 2015, Japanese
  • 心臓移植レシピエントとして検討を要した境界域知能例
    成田尚
    日本総合病院精神医学会, 28 Nov. 2014, Nominated symposium
    [Domestic Conference]
  • クロザピン開始後17年経過して発症した拡張型心筋症の1例
    大久保亮; 草地麻実; 納谷昌直; 成田尚; 橋本直樹; 久住一郎
    統合失調症研究, Mar. 2014, Japanese
  • 高次脳機能障害患者に維持透析導入の検討を要した1例
    磯山友幸; 成田尚; 林下善行; 賀古勇輝; 久住一郎
    精神神経学雑誌, 25 Oct. 2013, Japanese
  • 高次脳機能障害患者に維持透析導入の検討を要した一例
    磯山友幸; 成田尚; 林下善行; 賀古勇輝; 久住一郎
    日本精神神経学会総会プログラム・抄録集, 2013, Japanese
  • 当院における急性薬物中毒症例から考える医療連携
    成田 尚; 岩田 和也; 松永 力; 加藤 温
    精神神経学雑誌, 25 Jan. 2012, Japanese
  • 国立病院機構北海道医療センターにおける精神科身体合併症への取り組みについて
    成田 尚; 近藤 千尋; 松永 力; 加藤 温
    精神神経学雑誌, Oct. 2010, Japanese
  • MRI及び脳波検査で経過を追ったCJDの1例
    三宅 麻里衣; 成田 尚; 三戸 法和; 三上 敦大; 本間 次郎; 高田 秀樹; 吉田 悟
    精神神経学雑誌, Apr. 2010, Japanese
  • 悪性症候群後にaripiprazoleを投与した1症例
    成田 尚; 菅原 麻里衣; 三戸 法和; 三上 敦大; 本間 次郎; 高田 秀樹
    精神神経学雑誌, 25 Jan. 2010, Japanese
■ Syllabus
  • 基本医学研究, 2024年, 修士課程, 医学院
  • 基本医学総論, 2024年, 修士課程, 医学院
  • 応用社会行動科学, 2024年, 修士課程, 医学院
  • 医学総論, 2024年, 博士後期課程, 医学院
  • 基盤医学研究, 2024年, 博士後期課程, 医学院
  • 臨床医学研究, 2024年, 博士後期課程, 医学院
■ Affiliated academic society
  • Feb. 2025 - Present
    日本サイコカーディオロジー学会
  • Mar. 2024 - Present
    日本臨床精神神経薬理学会
  • Jan. 2023 - Present
    日本災害医学会
  • Japanese Society of Mood Disorders
  • 日本精神科救急学会
  • 日本精神神経学会
  • JAPANESE SOCIETY OF GENERAL HOSPITAL PSYCHIATRY
  • JAPANESE SOCIETY OF BIOLOGICAL PSYCHIATRY
■ Research Themes
  • 国内の移植医療推進10カ年戦略に関する研究
    Apr. 2025 - Mar. 2028
    成田尚
    厚生労働科学研究費, Others, 25FF1001
  • 拡散尖度画像による、躁うつ病と大うつ病患者の大脳白質構造差異について
    Grants-in-Aid for Scientific Research Grant-in-Aid for Early-Career Scientists
    01 Apr. 2020 - 31 Mar. 2024
    成田 尚
    北海道大学病院精神科神経科に通院もしくは入院中の躁うつ病および大うつ病の患者さんを対象とし、頭部MRIの撮像と同時に、対象患者の年齢、性別、発症時の年齢、罹病期間、使用中の向精神薬を調査した。双極性障害および大うつ病性障害の診断は、Diagnostic and Statistical Manual of mental disorders、 fifth edition(DSM-5)に基づいて確認した。また、双極性障害および大うつ病性障害の臨床症状はハミルトンうつ病評価尺度およびヤング躁病評価尺度を用い全ての項目を評価した。MRI 撮像はPhilips 社の3 テスラのMRI 装置であるAchieva TX)とSENSE-head-32 coil を用い、白質の評価のため拡散尖度画像を撮像し、同時に解析に必要なT1強調画像を撮像した。DKI データはDiffusional Kurtosis Estimator version 2.6.0 を使用して抽出を行い、その後T1 強調画像をStatistical Parametric Mapping version 12により分割化した。その後、T1強調画像をテンプレートに正規化し、その変換指標を拡散尖度画像に適応した。現時点で躁うつ病 20名、大うつ病性障害 20名のリクルートが終了した。症例数が予定していたサンプル数は概ね達成したが、引き続きリクルートをすすめていく予定である。また、共同研究の論文が「Microstructural Alterations in Bipolar and Major Depressive Disorders: A Diffusion Kurtosis Imaging Study.」のタイトルでJournal of magnetic resonance imagingにアクセプトされた。
    Japan Society for the Promotion of Science, Grant-in-Aid for Early-Career Scientists, Hokkaido University, 20K16638
  • Mean kurtosis alterations of cerebral white matter in patients with bipolar and major depressive disorders revealed by diffusion kurtosis imaging
    Grants-in-Aid for Scientific Research Grant-in-Aid for Research Activity start-up
    24 Aug. 2018 - 31 Mar. 2020
    Hisashi Narita
    In this study, we aimed to examine the differences of mean kurtosis (MK) and fractional anisotropy (FA) values between the patients with bipolar and depressive disorders using voxel-based analysis (VBA). Additionally, we examined the correlation between these values and severity of clinical symptoms in the patients. Compared to FA values, significant decreases in MK values were widely and extensively observed throughout the brains of patients with bipolar disorders. The MK values of frontal lobe were significantly negatively correlated with the severity of depressive symptoms. Thus, the diffusion kurtosis indices are suitable for evaluating altered WM structures in the human brain as they may detect white matter alterations of crossing fibers in mood disorders and assess the clinical state of patients.
    Japan Society for the Promotion of Science, Grant-in-Aid for Research Activity start-up, Hokkaido University, 19K21204
  • 統合失調症における拡散尖度画像を用いた白質構造変化と安静時機能画像の関連について
    黎風
    Jun. 2019
    成田尚
    北海道大学大学院医学研究院学術奨励基金, Principal investigator, Competitive research funding
■ Academic and Social Contribution Activities/Other
Industrial Property Rights
  • Frontiers in Psychology - Health Psychology, Associate Editor
    04 Oct. 2025 - Present
    Review
    Peer review etc
  • Frontiers in Psychology - Health Psychology, Editorial Board
    Jul. 2023 - Present
    Peer review
    Peer review etc
  • Frontiers in Psychiatry, Editorial Board
    Jun. 2023 - Present
    Peer review
    Peer review etc
  • 第123回日本精神神経学会学術総会 プログラム委員
    17 Jul. 2026 - 26 Jun. 2027
    Planning etc
  • 第39回日本総合病院精神医学会総会プログラム委員
    01 Mar. 2026 - 28 Nov. 2026
    Planning etc
    Academic society etc
  • Advances in Neuromodulation for Mood and Psychotic Disorders: Bridging Neurobiology and Clinical Practice in Asia
    06 Oct. 2026 - 08 Oct. 2026
    Planning etc, Panel chair etc
    Competition etc
    The 11th World Congress of Asian Psychiatry
  • 第37回日本総合病院精神医学会総会プログラム委員
    01 Apr. 2024 - 29 Nov. 2024
    Planning etc
    Academic society etc
  • 第31回日本精神科救急学会学術総会, プログラム委員
    Nov. 2022 - Oct. 2023
    Planning etc
    Academic society etc
  • 第30回日本精神科救急学会学術総会, プログラム委員
    Nov. 2021 - Oct. 2022
    Planning etc
    Academic society etc
Social Contribution Activities
  • DPAT 派遣時のCSCA_本部運営
    01 Nov. 2026 - 01 Nov. 2026
    Organizing member
    令和8年度北海道DPAT研修会
  • 令和8年度日本DPAT隊員技能維持研修
    12 Sep. 2026 - 12 Sep. 2026
    Advisor
  • 令和8年度 第1回厚真町メンタルヘルスサポートネットワーク連絡会
    26 Aug. 2026 - 26 Aug. 2026
    Lecturer
  • 札幌東陵高校フィールドワーク
    16 Jun. 2026 - 16 Jun. 2026
    Coverage cooperation
  • 令和7年度 秋田DPAT養成研修
    28 Feb. 2026 - 01 Mar. 2026
    Lecturer, Advisor
  • 令和7年度北海道DPAT研修
    23 Feb. 2026 - 23 Feb. 2026
    Lecturer
  • 自殺に関連する精神疾患と危険因子を学ぶ
    18 Feb. 2026 - 18 Feb. 2026
    Lecturer
    令和7年度厚真町ゲートキーパー講座
  • 令和7年度大規模災害訓練
    05 Sep. 2025 - 06 Sep. 2025
    Advisor, Organizing member
  • 令和7年度DPAT統括者・事務担当者研修
    26 Jul. 2025 - 27 Jul. 2025
    Lecturer, Advisor
  • 保護者によるキャリア教室
    19 Jul. 2025 - 19 Jul. 2025
    Lecturer
  • 令和7年度日本DPAT技能維持研修
    28 Jun. 2025 - 29 Jun. 2025
    Advisor, Organizing member
  • 令和6年度秋田DPAT養成研修
    23 Mar. 2025 - 23 Mar. 2025
    Lecturer, Advisor, Organizing member
  • 厚真町ゲートキーパー養成講座
    13 Mar. 2025 - 13 Mar. 2025
    Coverage cooperation, Lecturer
    厚真町 住民課 健康推進グループ
    ほっとニュース北海道 道央いぶりひだか
  • DPATの活動、意義、災害精神医療の課題について
    10 Mar. 2025 - 10 Mar. 2025
    Appearance, Coverage cooperation, Informant
    HBC
    「今日ドキッ!」内ニュース 放送後、YouTube公式「HBCnews」内での配信など
  • 令和6年度北海道DPAT先遣隊訓練
    09 Mar. 2025 - 09 Mar. 2025
    Advisor, Organizing member
  • 北海道ブロックDMAT実動訓練
    21 Dec. 2024 - 21 Dec. 2024
    Organizing member
  • DPAT本部運営
    24 Nov. 2024 - 24 Nov. 2024
    Lecturer, Advisor, Organizing member
    DPAT北海道研修
  • 北海道教育大学附属札幌中学校 インタビュー活動
    24 Jun. 2024 - 24 Jun. 2024
    Appearance
  • 令和6年DPAT先遣隊隊員技能維持研修
    15 Jun. 2024 - 15 Jun. 2024
    Advisor
  • 令和5年度青森県DPAT養成研修
    28 Feb. 2024 - 29 Feb. 2024
    Advisor, Organizing member
  • 令和6年能登半島地震 DPAT先遣隊派遣
    15 Jan. 2024 - 17 Jan. 2024
    Organizing member
  • 令和5年度DPAT先遣隊研修
    02 Dec. 2023 - 03 Dec. 2023
    Advisor, Organizing member
  • DPAT本部運営
    23 Nov. 2023 - 23 Nov. 2023
    Advisor, Organizing member
    DPAT北海道研修
  • 令和5年度大規模地震時医療活動訓練
    29 Sep. 2023 - 30 Sep. 2023
    Advisor, Organizing member
  • 令和5年度DPAT先遣隊隊員技能維持研修
    17 Jun. 2023 - 17 Jun. 2023
    Organizing member
  • 令和4年度北海道DAPT調整本部等立上げ訓練
    22 Feb. 2023
    Advisor
  • 令和4年度心の健康づくり推進協議会
    26 Jan. 2023
    Presenter, Advisor
  • 令和4年度大規模地震時医療活動訓練
    01 Oct. 2022
    Organizing member
  • DPATとは
    23 Sep. 2022
    Lecturer, Planner
    DPAT北海道研修
  • 令和4年度DPAT先遣隊研修
    27 Aug. 2022
    Advisor
  • 第1回心の健康づくり推進協議会
    14 Jul. 2022
    Panelist, Presenter, Advisor
  • 令和3年度心の健康づくり推進協議会
    24 Feb. 2022
    Presenter, Lecturer, Advisor, Organizing member
  • 令和 3 年度 DPAT 訓練・DPAT 体制整備共有会議
    23 Jan. 2022
    Organizing member
  • 令和 3 年度 DPAT 統括者 ・ 事務担当者研修
    03 Oct. 2021 - 03 Oct. 2021
    Lecturer
  • DPATとは・災害演習
    12 Sep. 2021 - 12 Sep. 2021
    Lecturer
    DPAT北海道研修
  • 令和2年度心の健康づくり推進協議会
    16 Dec. 2020
    Advisor
Media Coverage
  • DPATについて
    Oct. 2026
    Myself
    北海道新聞社
    [Paper]
  • 厚真町ゲートキーパー養成講座
    Apr. 2025
    Myself
    NHK
    [Media report]
  • DPATの活動、意義、災害精神医療の課題について
    Mar. 2025
    Myself
    HBC
    今日ドキッ!
    [Media report]